force_id,pt_report,xgb_report,psu_occlusion,pt_psu_gt,gpt_5shot_response,gpt_7shot_response,human_assessment5,human_assessment7,yesno_gt
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01098548].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost modelâ€™s estimated probability of 0.01098548 suggests a very low likelihood of the diagnosis being 'yes,' indicating that it is quite rare among similar patients. Furthermore, among the similar patient cohort, there is no indication of a prevalent diagnosis of seizures, particularly in the context of the patients with similar surgical histories and cardiac diagnoses (such as Atrioventricular canal defect). The overall health history of the main patient, which lacks recorded neurological complications, aligns with this prediction, supporting the conclusion that the occluded outcome is likely negative.","Based on the data provided, the prediction for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is ""no."" The XGBoost model analysis indicates a low predicted probability (0.01098548) for the occluded outcome, suggesting a strong likelihood that seizures did not occur. 

Moreover, when examining similar patients with comparable surgical histories and conditions, it is observed that many of them do not report a history of seizures. The majority of similar patients also do not exhibit significant neurological complications, which further reinforces the likelihood that this main patient has not experienced seizures requiring treatment.",1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00078829].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the analysis of the main patient and the similar patients, it is reasonable to predict that the main patient does not have a history of pacemaker placement. The main patient has not undergone any cardiac interventions that would typically necessitate a pacemaker, such as significant arrhythmias or structural heart block as indicated by their CMR and surgical history. 

Furthermore, among the similar patients, there is a pattern where a lack of interventions (like those seen in the main patient) corresponds with a lower incidence of pacemaker placements. The XGBoost model also indicates a very low probability (0.00078829) for the occluded outcome of having a pacemaker, reinforcing that it is unlikely that the main patient has this history. Thus, considering these factors, it is predicted that the answer is **no**.","Based on the provided data, the predicted missing clinical outcome for the main patient, if they have a history of pacemaker placement, is **no**. The main patient has complex surgical history tied to congenital heart defects but has not undergone a pacemaker placement according to the detailed surgical history. Additionally, the model's predicted probability of 0.00078829, combined with a strong performance in identifying positive cases (46 predicted Yes out of 711 instances), suggests that the likelihood of this patient being in the 'yes' category (having a history of pacemaker placement) is exceptionally low. Furthermore, similar patients, particularly those with complex conditions and surgical histories, have not exhibited a trend of requiring a pacemaker unless explicitly indicated, reinforcing the likelihood that this patient does not have such a history.",1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03919285].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, it is predicted that the main patient has not died. The XGBoost model assigns a low predicted probability of 0.039, indicating that the likelihood of the outcome ""Has the patient died?"" being 'yes' is quite low. Furthermore, similar patients, especially those with comparable surgical histories and cardiac diagnoses (e.g., atrioventricular canal defects and Fontan procedures), were also found to have a survival rate with no recorded fatalities. This trend, combined with the high classification accuracy of the model (96%), strengthens the conclusion that this patient is likely alive, given the absence of significant comorbidities typically associated with higher mortality in this population.","Based on the data provided, the predicted outcome for the main patient regarding whether they have died is **""no.""** This prediction is reinforced by the fact that the XGBoost model estimates a 3.92% probability that the patient has died, which is significantly low and indicates a strong likelihood of survival. Additionally, the main patient has a history of successful surgeries, including a lateral tunnel Fontan with fenestration, which generally correlates with better outcomes. Furthermore, when considering the similar patients, none in the cohort seem to have died, further supporting the conclusion that this patient is likely alive.",1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06742494].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the data provided, I predict that the main patient does **not** have a history of ascites (> trace). The main patient has not exhibited complications such as protein-losing enteropathy or pleural effusions after surgery, which are often associated with the development of ascites. Additionally, the similar patients show a trend where those with a similar surgical history (Fontan), known complications, and a lack of significant cardiac or hepatic issues also reported no history of ascites. Lastly, the XGBoost model's predicted probability of the occluded outcome being 'yes' is very low (6.74%), suggesting a high likelihood that this patient did not experience ascites.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). The main patient, who has undergone multiple cardiac surgeries and has a known diagnosis of atrioventricular canal defect with suspected heterotaxy, exhibits stable conditions in their clinical history with no reported complications related to ascites. Among the similar patients, those with a comparable surgical and clinical profile, many also do not present with ascites, suggesting a trend. The XGBoost model suggested a low probability of the occluded outcome being positive (0.0674), supporting the hypothesis that this patient's history of ascites is also likely negative when considering the data provided.",1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00292091].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the comprehensive data provided for the main patient and the insights derived from similar patients, it is predicted that the main patient did **not** receive a heart transplant. The patient's relatively stable status, absence of severe complications or major acute events, and a low predicted probability (0.0029) of requiring a transplant align with the outcomes observed in similar patients, most of whom did not require transplants either. Additionally, the characteristics of the main patient's surgical history, particularly the lack of significant post-operative complications seen in similar cases, suggest a favorable clinical trajectory, decreasing the likelihood of them needing a heart transplant.","Based on the data provided for the main patient and the similar patients, it is reasonable to predict that the main patient did **not** receive a heart transplant. The XGBoost model's predicted probability of 0.0029 suggests a very low likelihood of the patient receiving a transplant, indicating strong confidence that it did not occur. Additionally, reviewing the similar patient's surgical histories, many have not undergone heart transplants, particularly in cases involving complex congenital heart defects where alternative interventions, such as a Fontan procedure, are prioritized. The patient's own history and clinical details align with those who typically manage their conditions without resorting to transplantation, further supporting this prediction.",1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.2804787].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data and analysis, the missing clinical outcome for the main patient is predicted to be **""no,""** indicating that the patient does not have a history of ascites (> trace). This prediction is supported by the main patient's surgical history, which does not indicate any significant complications related to fluid retention or liver issues that could lead to ascites. Furthermore, among the similar patients, there is a notable absence of reported ascites in combination with their surgical histories and ongoing conditions, particularly those who have undergone similar Fontan procedures without complications leading to significant fluid accumulation. The XGBoost model further corroborates this conclusion, predicting a low probability (0.2804787) for the occurrence of the occluded outcome, indicating that ascites is unlikely to be present in this case.","Based on the available data, I predict that the main patient does **not** have a history of ascites (> trace). Firstly, the main patientâ€™s MRI findings indicate mild regurgitation and show no evidence of significant complications, which often accompany ascites. Additionally, the similar patients' cohort presents varied histories but leans towards those with more severe conditions and histories of ascites, particularly those with associated complications post-Fontan. The XGBoost modelâ€™s estimated predicted probability of 0.2804787 suggests a relatively low chance of having a history of ascites, which aligns with the overall trends noted in the patient's features and the similar patients' outcomes. Therefore, considering these observations, it's reasonable to conclude that the main patient likely does not exhibit a significant history of ascites.",1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02138278].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, I predict that the main patient has not died. The XGBoost model indicates a very low predicted probability of 0.02138 for the occluded outcome ""Has the patient died?"" This low score suggests strong confidence that this outcome did not occur. Furthermore, examining the similar patients reveals that those who underwent comparable surgeries and had similar MRI findings, such as tricuspid valve interventions and Fontan procedures, have also not died. The fact that the main patient has a history of regular monitoring and no indication of severe complications alongside a strong AUC-ROC of 0.87 support this conclusion, reinforcing the likelihood of survival post-surgery.","Based on the information provided, the predicted probability for the occluded outcome ""Has the patient died?"" is approximately 0.021, suggesting a very low likelihood of mortality. Additionally, the similar patients, particularly those with comparable cardiac diagnoses and surgical histories, mostly maintained survival post-Fontan despite facing other complications such as thrombus, arrhythmias, or pleural effusions. Given the main patient's extensive surgical history with interventions targeting the tricuspid valve and uneventful post-operative recovery without significant early complications, it appears reasonable to predict that the main patient has not died. Therefore, I would conclude that the appropriate prediction for the occluded outcome is ""no.""",1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00061804].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, the predicted outcome for the main patient regarding whether they received a heart transplant is likely **no**. The patient's surgical history indicates multiple interventions, including the Fontan procedure, but there have been no indications or records of a heart transplant. Furthermore, although the XGBoost model yields a low probability (0.00061804) for the outcome indicating heart transplant, it reflects the overall trends in the cohort, where only a limited number of patients received a transplant. In addition, the majority of similar patients with comparable conditions and interventions did not undergo heart transplantation, suggesting that it is relatively uncommon in patients with complex congenital heart disease who have undergone the Fontan procedure without significant complications that would necessitate transplantation.","Based on the provided information and the XGBoost model's prediction, the likelihood of the main patient receiving a heart transplant is very low, with the model estimating a probability of only 0.0006 for this outcome. This aligns with the main patient's history, which indicates no previous heart transplant and a complex surgical history involving multiple procedures associated with a Fontan pathway and myocardial management, rather than transplantation. Moreover, a review of similar patients suggests a similar trend; many had significant medical complexities and additional interventions without leading to a heart transplant requirement, indicating that the main patient is possibly in a similar situation regarding their clinical outcome. Therefore, the prediction is that the main patient did not receive a heart transplant.",1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.09811153].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The significant evidence comes from the predicted probability of 0.09811153 from the XGBoost model, which suggests a low likelihood of the condition being present. Additionally, the similar patients with comparable cardiac histories and surgical interventions, including patients with atrioventricular valve procedures and specific diagnoses, showed a much lower prevalence of seizures. Most of them did not exhibit this diagnosis, which aligns with the low predicted probability for the main patient. Hence, the conclusion strongly indicates that seizures are unlikely in this case.","Based on the provided data, it is likely that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model predicts a very low probability (0.098) for the occluded outcome occurring, indicating a high likelihood that the patient has not had this diagnosis, especially since the overall cohort demonstrated a high validation accuracy of 94% and an AUC of 0.86. 

Moreover, reviewing the surgical history and clinical characteristics of similar patients shows that most of those with significant cardiac issues did not report a history of seizures. This trend, coupled with the lack of such a diagnosis in the main patient's own history, supports the conclusion that it is unlikely he suffers from seizures. Consequently, the diagnosis of seizures requiring antiepileptic medications should be predicted as ""no.""",1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00101269].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided information, the predicted outcome for whether the main patient has a history of pacemaker placement is **no**. The main patient has a complex surgical history, including a tricuspid valve procedure and an atriopulmonary Fontan, but there is no indication of prior pacemaker placement in their records. 

Similarly, the cohort of similar patients shows that while some did have histories of pacemaker placement, they typically had more direct complications such as atrial tachyarrhythmias or heart failure requiring intervention. The missing outcome prediction from the XGBoost model, which indicates an extremely low probability of the outcome being 'yes' (at just over 0.1%), supports the conclusion that the main patient likely does not have a history of pacemaker placement. The absence of documented arrhythmias or major complications commonly associated with pacemaker placements further corroborates this finding.","Based on the clinical history and the data from the main patient, it is highly likely that the patient does **not** have a history of pacemaker placement. The patient has a complex surgical history involving multiple interventions (including multiple surgeries and tricuspid valve procedures), which may increase the risk for arrhythmias; however, they also have no documented history of significant ventricular arrhythmias that would typically necessitate a pacemaker. 

Additionally, when considering similar patients, most have similar profiles (Fontan procedures, ventricular morphology) and histories of arrhythmias, but pacemaker placement is evident only in cases with a more pronounced history of sustained ventricular arrhythmias or significant complications. Given the XGBoost model's prediction probability of 0.00101269 for the occluded outcome being 'yes,' the data strongly suggests that the patient likely does not have a pacemaker placement history. Thus, the expected outcome for this patient is **no**.",1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0024228].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"**Prediction: No, the patient has not died.**

The XGBoost model estimates a very low probability (0.0024228) of the occluded outcome, which in this case is death, indicating that it strongly favors the outcome of survival. Looking at the surgical history of the main patient, they have undergone a significant number of interventions, including tricuspid valve repair and placement of a dual-chamber pacemaker, yet they continue receiving care and monitoring, suggesting ongoing stabilization and management of their condition. Furthermore, similar patients with comparable structural anomalies and surgical histories have shown a tendency for survival, with none of the analogous records indicating mortality. This, combined with the high performance metrics of the model and successful interventions in the main patient's treatment, supports the reasoning that this patient is likely alive.","Based on the provided data, it is predicted that the main patient has likely not died. The XGBoost model indicates a very low probability (0.0024228) that the outcome ""has the patient died?"" is 'yes', suggesting a strong confidence that the patient is alive. Additionally, the surgical history and clinical outcomes of similar patients indicate a pattern where individuals with a complex surgical history involving multiple interventions, such as the main patient with Fontan surgery and further modifications, often survive longer when managed appropriately. Furthermore, the similar patients' outcomes consistently show no recent deaths reported, even with overlapping challenges such as heart failure and arrhythmias, suggesting that the main patient's prognosis remains favorable as long as their condition is monitored and treated effectively.",1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00478739].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the data provided for the main patient, the XGBoost model predicts a probability of only 0.0048 for the outcome ""Did the patient receive a heart transplant?"" indicating a very low likelihood that this patient underwent a transplant. Moreover, the main patient's extensive surgical history involving multiple interventions prior to and including the Fontan procedure, along with a lack of significant complications such as protein-losing enteropathy or other severe issues observed in similar patients, suggests that their clinical condition remains relatively stable. 

Similar patients have shown varied outcomes: some have received transplants later due to complications such as protein-losing enteropathy or significant arrhythmias, which are not reported in the main patient's case. Therefore, combining the model's prediction and clinical insight into the main patient's stable status, it is reasonable to conclude that the patient most likely did not receive a heart transplant. Thus, the outcome is predicted to be ""no.""","Based on the information provided for the main patient, the estimated probability of receiving a heart transplant is very low at approximately 0.48%. Additionally, this patient's surgical history indicates significant interventions consistent with complex congenital heart disease, and the history of multiple surgeries does not imply a successful transition to transplant candidacy. 

Examining the similarities with the cohort, many patients with similar profiles have undergone complex surgeries without progressing to a heart transplant, highlighting that interventions such as Fontan procedures can often suffice in managing their care. Given the prediction from the XGBoost model, which indicates a 0.48% likelihood and the lack of compelling indicators in the clinical history pointing toward transplant, it is reasonable to conclude that the main patient did not receive a heart transplant.",1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00754037].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided information, I predict that the main patient does **not have** a history of ascites (> trace). The patient's surgical history, particularly undergoing a lateral tunnel Fontan with a fenestration, often correlates with complications such as protein-losing enteropathy and possible ascites, yet the model's predicted probability of 0.0075 strongly suggests a low likelihood for such outcomes. Additionally, similar patients with a recent history of ascites typically also had complex surgical backgrounds, and they show a higher correlation with the outcomes than the available similarities in the main patient's profile. Hence, despite the potential risks that come with a fenestrated Fontan, the overall profile leans towards an absence of significant accumulations in this patient.","Based on the provided data, it is reasonable to predict that the main patient does **not** have a history of ascites (> trace). The main patient's significant cardiac history and surgical background, including multiple prior surgeries and the presence of structural anomalies, suggest a complex clinical course; however, there are no recorded instances of ascites in the history. Additionally, in the cohort of similar patients, there is a mix of outcomes, but all patients with a history of ascites also had significant complications related to their status post-Fontan procedure, while the main patient does not exhibit indicators typically associated with such complications (e.g., significant liver dysfunction or elevated fibrosis tests that could predispose to ascites). The XGBoost model also indicates a very low probability (0.00754037) of the occluded outcome, reinforcing the notion that problematic fluid retention like ascites is likely absent in this case.",1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03521026].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the information provided, the predicted outcome for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is **no**. The XGBoost model predicts a low probability of the occluded outcome being 'yes' (0.035), indicating that seizures are unlikely to be diagnosed in this case. Additionally, a review of similar patients shows that despite their complex cardiac histories, many have not reported seizures, particularly those with similar procedures and diagnoses, such as Double Inlet Left Ventricle and Tricuspid Atresia. Furthermore, the main patient exhibits no significant neurological complications in their recorded history or MRI evaluations, aligning with the trends observed in these similar cases.","Based on the provided information, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model predicts a low probability of the occluded outcome being 'yes' (0.0352), suggesting that the model finds the characteristics associated with seizures to be infrequent in similar patient cohorts, despite some patients having other comorbidities. Furthermore, examining the data of similar patients, few exhibit a seizure diagnosis, and the overall history of seizures among similar cases appears limited, particularly in those with comparable surgical histories and outcomes. Therefore, the likelihood that the main patient has a seizure diagnosis remains low, supporting the prediction that it is absent.",1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.97609097].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the XGBoost model's predicted probability of 0.976, there is a strong indication that the main patient has a history of pacemaker placement. The detailed clinical and surgical history of the main patient includes significant cardiac interventions, such as tricuspid valve repair and the placement of a CRT dual-chamber pacemaker, which aligns with the needs seen in complex single-ventricle patients. Furthermore, trends in the similar patient cohort indicate that pacemaker placement is common among those with severe atrioventricular valve regurgitation and other complications, similar to the main patient's catheterization and surgical history. The accuracy and robustness of the model, combined with the context provided in both the main and similar patients' histories, reinforce the likelihood that the occluded outcomeâ€”having a history of pacemaker placementâ€”is indeed 'yes'.","Based on the main patient's surgical history and the comparisons drawn from similar patients, it is likely that the main patient has a history of pacemaker placement. The main patient has undergone several significant cardiac surgeries, including a recent tricuspid valve repair and placement of a CRT dual-chamber pacemaker system. Among the similar patients, one patient with a comparable surgical background (Damus-Kaye-Stansel, Fontan, and various additional interventions) also demonstrated a notable history of pacemaker placement, underlying the prevalence of such interventions in this specific population. Furthermore, the XGBoost model's high probability estimate (0.976) indicates a strong likelihood for this outcome in light of the complex medical history inherent to single-ventricle patients post-Fontan surgery. Therefore, it is reasonable to predict that the main patient does have a history of pacemaker placement.",1,1,1
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01061994].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the data provided, I would predict that the main patient does **not** have a history of ascites (> trace). This conclusion is supported by the XGBoost model's prediction probability of 0.0106, which suggests a very low likelihood of ascites being present. Furthermore, in reviewing both the main patient's clinical and MRI findings, there is no indication of fluid overload or liver dysfunction that commonly associates with ascites. Additionally, amongst the similar patients, none exhibited a significant history of ascites, reinforcing the notion that this patient is also less likely to experience fluid accumulation given the clinical features and prior surgeries that align.","Based on the provided data, the predicted outcome for whether the patient has a history of ascites (> trace) is ""no."" The main patient has no recorded history of ascending aorta or arch interventions, and all other assessed clinical parameters such as normal hepatic function tests and unremarkable post-operative observations further support this prediction. 

Additionally, the similar patients, many of whom have undergone procedures similar to the main patient's, also show no significant instances of ascites. The XGBoost model's prediction probability of 0.0106 indicates a strong inclination towards a negative outcome, suggesting that the occluded outcome of ascites is unlikely based on the preceding clinical history and MRI evaluations.",1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03477965].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data and model predictions, it is predicted that the main patient **does not have a diagnosis of seizures requiring antiepileptic medications**. The XGBoost model yielded a low probability (0.0348) for the occluded outcome being 'yes,' indicating a strong likelihood of the outcome being 'no.' Additionally, examining the similar patients reveals that while many of them have experienced various cardiac interventions and complications, they do not show significant evidence of seizure-related diagnoses, further supporting the notion that the main patient's condition may not involve seizures. The patient's overall stable clinical course and the absence of any documented history of seizures or significant arrhythmias contribute to this conclusion.","The missing clinical outcome for the main patient, regarding whether they have a diagnosis of seizures requiring antiepileptic medications, is likely ""no."" This prediction is supported by the fact that the main patient has a history of sinus node dysfunction and has undergone various surgeries, including those for a double inlet right ventricle and Fontan procedure, but no history of seizures or significant arrhythmias is mentioned in their status updates. 

Additionally, the data from similar patients with comparable surgical histories reveal a significantly lower occurrence of seizures; for example, among similar patients, the majority do not report a seizure diagnosis. Furthermore, the XGBoost model's predicted probability of the seizure outcome being ""yes"" is low at 0.0348, indicating that seizures are relatively rare in this patient cohort, thereby reinforcing the probability that the main patient does not have a seizure diagnosis.",1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01886172].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the data provided, the model predicts a very low probability (approximately 0.0189) of the occluded outcome (death) for the main patient. Furthermore, the extensive surgical history, including the successful Fontan procedure with a fenestration and the absence of critical complications like ventricular tachyarrhythmias, heart transplantation, or any severe systemic issues, suggests reasonable stability. Additionally, the similar patients, who have undergone analogous surgical procedures, show a common trend of maintaining their status without fatal outcomes, supported by the model's strong performance metrics (accuracy of 0.96). Therefore, considering all these factors, it is reasonable to predict that the main patient has not died (outcome = 'no').","Based on the provided information, the prediction for the outcome ""Has the patient died?"" is **no**. The main patient has a clinical history that includes multiple surgeries but no significant complications such as necrosis or thrombus formation, which are common precursors to mortality in similar patients, suggesting a level of stability. 

Moreover, the XGBoost model predicts a very low probability (0.0188) for the occluded outcome of death, indicating a high confidence in the patient's survival based on the features and comparisons with similar patients. Additionally, similar patients with comparable surgical histories and clinical conditions show that the majority continue on without mortality, further supporting the conclusion that the main patient is likely alive.",1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00294164].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, I predict that the main patient did **not** receive a heart transplant. Although the patient has undergone multiple cardiac surgeries and had a complex surgical history, including a Fontan procedure, the data from similar patients shows low rates of heart transplantation in this cohort. The prediction probability from the XGBoost model indicates a very low likelihood (0.0029) of the outcome being 'yes' for a heart transplant. Additionally, the similar patients, particularly those with outcomes related to Fontan procedures, had complications but did not reach the threshold for transplantation, suggesting that the main patient's condition is likely contextualized similarly. Therefore, I believe the main patient also did not receive a heart transplant.","Based on the available data, I predict that the main patient **did not receive a heart transplant**. The likelihood of having had a heart transplant in similar cases is relatively low, evidenced by an occluded outcome probability of approximately 0.0029 from the XGBoost model, suggesting that only 0.29% of similar patients underwent a transplant. Furthermore, the main patient has undergone multiple cardiac surgeries but shows no indication of significant complications or deterioration that would typically necessitate such a procedure. Similar cohorts indicate that while patients with complex conditions like hypoplastic left heart syndrome or major structural anomalies may eventually require heart transplants, the data here suggests that most remain managed through other interventions without progressing to transplant.",1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9987472].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the main patient has a history of pacemaker placement (yes). The main patient exhibits several risk factors commonly seen in similar patients who underwent complex surgeries associated with single-ventricle physiology, such as atrial tachyarrhythmia and sinus node dysfunction, which often lead to the need for pacing interventions. In addition, among similar patients, those with comparable surgical historiesâ€”including multiple cardiac surgeries and complex anatomyâ€”have shown a history of pacemaker placement as an intervention to manage arrhythmias. The high predicted probability (0.9987472) from the XGBoost model further strengthens this inference, indicating a strong likelihood that the occluded outcomeâ€”having a history of pacemaker placementâ€”applies to this patient as well.","Based on the information provided, it is predicted that the main patient has a **history of pacemaker placement: no**. The main patient has undergone multiple surgeries and interventions, but there is no indication in their surgical history of a pacemaker being placed. Additionally, the similar patients' profiles reinforce this prediction; many of them, particularly those who underwent extensive cardiac surgeries with comparable factors such as ventricular morphology and the type of Fontan procedure, also do not have pacemaker histories. The strong prediction from the XGBoost model, which indicates a high probability of the occluded outcome being 'no' (0.9987472), along with the patterns observed in similar patients, supports this conclusion.",1,0,1
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? yes
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00752878].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the available data and the output from the XGBoost model, I predict that the main patient did not receive a heart transplant. The model indicates a low probability (0.0075) of the occluded outcome being 'yes', which suggests that heart transplant is unlikely for this patient. Additionally, the main patient has a history of significant medical issues, including pulmonary and vascular complications, as indicated by their surgical history and MRI findings. Similar patients who underwent multiple cardiac surgeries, such as those in the analyzed cohort, seem to have low rates of receiving transplants, particularly when they display ongoing complications that can complicate eligibility. Given all these factors, it is reasonable to conclude that a heart transplant was not performed in this case.","Based on the analysis of the provided data, it is predicted that the main patient did **not** receive a heart transplant. The XGBoost model's predicted probability of the occluded outcome being 'yes' is only 0.0075, which indicates a very low likelihood of transplant occurrence. Furthermore, reviewing the similar patients reveals that most had either complex congenital heart defects or were managed successfully without transplantation, showing trends towards conservative management and interventions that allow for better outcomes without needing heart transplants. The main patient's surgical history and current status also indicate a stable albeit complex clinical picture, further reinforcing the notion of continued management without the need for a transplant.",1,1,0
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.3674904].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,"[' Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure\r\nShe was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""\n Has the patient died? yes\n If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest\n']","Based on the provided data, the predicted outcome for whether the patient has died is ""no."" This is supported by the relatively stable condition reflected in the patient's MRI reports, such as an acceptable ejection fraction and no significant complications such as protein-losing enteropathy or major thrombus history that correlate with higher mortality rates. Furthermore, the similar patients' histories show that despite shared risk factors like complex cardiac diagnoses and the need for multiple surgeries, none of the referenced patients reported death, which aligns with the main patient's context and conveys a degree of optimism regarding their prognosis. The XGBoost model's prediction probability of 0.3674904 implies a low likelihood of death in this cohort, further reinforcing the assessment of survival for the main patient.","**Prediction:** No, the patient has not died.

**Reasoning:** The main patient underwent extensive cardiac surgeries, including a Fontan procedure, which tends to improve survival in single-ventricle patients, particularly when there is no significant post-operative complications. The longitudinal data from similar patients shows that those with similar histories without significant peri-operative events or major complications have high survival rates. Additionally, the XGBoost model indicates a probability of 0.3674904 for the occluded outcome indicating the patient died; although lower than 0.5, it still reflects a better likelihood of survival. This aligns with the clinical trends observed in patients after Fontan surgeries, where the survival odds improve substantially. 

Overall, given the context of the main patientâ€™s history and the data trends from similar patients, it is reasonable to conclude that the patient has not died.",0,0,1
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.6338589].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? yes\n'],"Based on the information provided, I would predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. This conclusion is supported by the fact that the main patient had significant cardiac history, including multiple surgeries and a known history of complications such as a thrombus but no mention of seizures in the available medical records. In contrast, the similar patients also did not exhibit a strong correlation between their surgical histories and the presence of seizures, as only a minority had reports of such complications. Furthermore, given the XGBoost model's predicted probability of 0.6338589 for the occluded outcome being 'yes', which is below the threshold of significance, it also indicates that the likelihood of the patient having seizures is not high. Thus, consolidating all these insights, the evidence leans toward the absence of a seizure diagnosis requiring treatment in this patient.","Based on the data provided, it is likely that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model predicts a 63.4% probability of having seizures, but considering the low recall of 7% for those diagnosed with seizures in the model and the fact that similar patients, despite having complex surgical histories and varying cardiac anomalies, show no significant prevalence of seizure diagnoses, this suggests a less favorable likelihood for our patient. Additionally, the main patient's history of atrial tachyarrhythmias, without any reported evidence of seizures or neurological issues in both their outcomes and the similar cohort, further supports this prediction. Thus, while the model indicates a potential for seizure diagnosis, the overall clinical context leans towards a ""no.""",0,0,1
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.15205666].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the information provided, I predict that the main patient **does not have a history of ascites** (> trace). The patient has undergone multiple cardiac surgeries, including a lateral tunnel Fontan, which can be associated with complications such as protein-losing enteropathy but without evidence of chylous pleural effusions or significant liver dysfunction. The similar patients, while facing similar surgical histories and conditions (such as hypoplastic left heart syndrome and complex heart defects), exhibited some positive trends in the context of ascites, but most reported histories were negative. Specifically, the model predicted a low probability (0.152) for the outcome being ""yes,"" and the XGBoost model performed well in predicting these outcomes, suggesting that the likelihood of presence of ascites is low based on the patientâ€™s characteristics and comparable outcomes from similar patients.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). The main patient has a reported history of significant respiratory distress and pedal edema leading up to their death, but no direct mention of ascites is provided, suggesting that fluid accumulation in the abdomen may not have been present or significant enough to warrant reporting. Furthermore, similar patients with a history of ascites also show a range of other concerning clinical outcomes, including elevated liver fibrosis markers and significant arrhythmias. Given that this patient's predicted probability from the XGBoost model points towards a lower likelihood (0.15205666), reinforcing the likelihood of a 'no' response for ascites based on the clinical picture suggests that ascites was not a contributing factor in this patient's condition.",1,1,0
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00105251].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the analysis, the predicted outcome for whether the patient has a history of pacemaker placement is ""no."" The main patient has undergone a complex surgical history typical for those with single-ventricle anatomy, and she is reported as having survived multiple surgeries without any indication of a pacemaker placement. Additionally, in examining similar patients, the majority also did not have a history of pacemaker placement despite experiencing similar surgical interventions, with most maintaining stable conditions without requiring such devices. The XGBoost modelâ€™s low probability estimate of the occluded outcome (0.00105251) further supports the conclusion that it is unlikely the patient would have had a pacemaker placed, as the overall evidence from both the patient's and similar patients' histories aligns with the absence of this intervention.","Based on the data provided, it is predicted that the main patient does not have a history of pacemaker placement. The XGBoost model yields a predicted probability of 0.00105251 for the outcome being 'yes,' which is very low, indicating a strong modelled belief that the patient likely has not received a pacemaker. Additionally, the surgical histories of the similar patients indicate that many have not undergone pacemaker placement, particularly those with similar cardiac compositions and surgical backgrounds, such as similar surgeries and diagnoses. Given the main patient's profile and these observations, it is reasonable to conclude he does not have a history of pacemaker placement.",1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02666651].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, I predict that the main patient has **not died**. The XGBoost model predicts a probability of 0.0267 for the occluded outcome being 'yes', which is a very low probability indicating that the likelihood of death is minimal. Additionally, the main patient has a robust clinical profile with no severe complications post-Fontan surgery, and similar patientsâ€”many of whom share key surgeries and clinical characteristicsâ€”also demonstrate high survivability rates. The historical data of similar patients supports a positive prognosis, suggesting stability and a reduced risk of mortality for this particular patient.","Based on the information provided for the main patient and the similar patients observed, I predict that the main patient has **not died**. The XGBoost model gives a very low probability of 0.0267 for the occluded outcome, indicating a strong prediction that the event (death) did not occur. Additionally, similar patients with comparable surgical histories, such as the presence of a bidirectional Glenn and being classified under a category with hypoplastic structures, have mostly shown survival without significant predictive values indicating fatal outcomes. This supports the conclusion that the main patient's status is stable relative to the cohort.",1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00946598].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the predicted outcome for the main patient with respect to having a history of ascites is **no**. The main patient has undergone extensive cardiac surgeries, including a successful lateral tunnel Fontan, and all previous assessments have indicated an absence of ascitic complications. Furthermore, a review of similar patients with comparable surgical histories indicates that while a small number had a history of ascites, many did not develop this complication following similar surgical interventions. Additionally, the output from the XGBoost model predicts a very low probability (0.0095) of the occluded outcome being 'yes', reinforcing the likelihood that this patient does not have a history of ascites.","Based on the available data, the predicted outcome for the main patient regarding whether they have a history of ascites (> trace) is **""no.""** The main patient has no indicated history of ascites, chylous effusions, or notable concerning history post-Fontan, such as significant liver dysfunction or complications that commonly lead to ascites. Additionally, the similar patients analyzed also show a trend of no ascites presence in their outcomes, particularly given that they have a similar surgical history (extracardiac Fontan) and associated interventions (like bidirectional Glenn surgeries) without the complication of ascites noted. The XGBoost model reinforces this prediction with a low probability assessment (0.00946598), supporting the conclusion that ascites is unlikely present in the main patient.",1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00105511].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the data provided, the missing clinical outcome is predicted to be **""no,""** indicating that the patient does not have a history of pacemaker placement. This prediction aligns with the similar patients whose surgical histories reflect comparable patterns; none of them had undergone pacemaker placements. Furthermore, the main patient's cardiac status post-Fontan procedure, including notable features like mild atrioventricular valve regurgitation and absence of significant structural heart complications (aside from described conditions), suggests that while complications can arise post-surgery, a pacemaker placement may not have been necessary in this case. The XGBoost model's low predicted probability (0.00105511) of the occluded outcome being 'yes' supports this conclusion, reinforcing that the likelihood of pacemaker intervention is very low within this context.","Based on the analysis of the main patient's data and the outcomes observed in similar patients, it is likely that the patient does **not** have a history of pacemaker placement. The main patient has a history of three cardiac surgeries, including a lateral tunnel Fontan and a bidirectional Glenn, but there are no documented interventions involving pacemaker placements or significant arrhythmias that would typically necessitate such a procedure. Furthermore, the similar patients showed varying outcomes with some having a pacemaker placement but a majority did not, particularly those with similar conditions and interventions as the main patient. The XGBoost model further supports that the likelihood of having a pacemaker is low given the prediction probability of 0.00105511, indicating that the occluded outcome (i.e., history of pacemaker placement) is more likely to be 'no' rather than 'yes'.",1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00757991].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data and the XGBoost model's prediction, it is highly unlikely that the main patient received a heart transplant, with a predicted probability of only 0.00757991. The main patient has undergone multiple surgeries, including a lateral tunnel Fontan and has experienced conditions such as mild atrioventricular valve regurgitation, suggesting he is managing with his current heart architecture. Among the similar patients analyzed, those with comparable surgical histories and anatomical conditions generally did not progress to transplant, as indicated by the data that identifies patterns of successful management without requiring a transplant. Therefore, I would predict that the occluded outcomeâ€”whether the patient received a heart transplantâ€”would be ""no.""","Based on the analysis of the main patient's clinical and surgical history, the predicted clinical outcome for the question ""Did the patient receive a heart transplant?"" is **no**. The main patient has undergone several previous cardiac interventions including Fontan surgery, but there is no record of being listed for a heart transplant or receiving one, which suggests that the need for transplantation was likely not indicated. 

Furthermore, the XGBoost model predicted a very low probability (0.00757991) of needing a heart transplant, which aligns with the outcomes observed in the similar patients who generally had more severe cardiac conditions and yet did not all undergo transplantation. The considerable accuracy and specificity of the model support the assertion that this patient has not received a heart transplant, reinforcing the conclusion drawn from both their individual history and comparative data.",1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.43401805].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided information, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a relatively mild medical history, with no documented history of seizures, strokes, or long-term complications commonly associated with seizure disorders. 

Furthermore, the similar patients' group shows a low incidence of seizure diagnoses, and none of the similar patients listed had a history of seizures. Even though the XGBoost model predicts a probability of 43.4% for the presence of seizures (suggesting some uncertainty), given the overall context and absence of definitive indicators linking seizure diagnosis to this particular case or the similar cohort, the patient is likely seizure-free. Thus, the most sensible inference, considering all these factors, leans toward a negative outcome for seizures in this patient.","Based on the provided data, it is likely that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The prediction probability of the occluded outcome being 'yes' is approximately 0.43, which indicates a near even chance of having seizures; however, this value is further supported by the fact that among the similar patients, none reported a history of seizures. Furthermore, the main patient's surgical history, consisting of a total of three cardiac surgeries without complications involving neurological issues or a history of peri-operative strokes, suggests a more stable clinical course. Consequently, this combination of evidence indicates that it is reasonable to conclude that the main patient does not have a diagnosis of seizures.",1,1,0
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.5943146].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the XGBoost model's estimated probability of 0.5943146 for the occluded outcome being 'yes' and the data provided for the main patient, there is a significant likelihood that this patient does indeed have a history of ascites. The main patient has a notable clinical history, including renal dysfunction and a significant history of pleural effusions, which can create a predisposition for fluid accumulation and potentially lead to ascites. 

Moreover, similar patients who underwent comparable surgical interventions, such as the Fontan procedure, often exhibit trends of fluid accumulation, particularly in those with renal dysfunction or past cardiac complications. These factors, alongside the model's robust performance metrics indicating it has accurately classified several patients with analogous cardiac profiles, further support the likelihood of the main patient having a history of ascites. Therefore, I would predict that the patient does have a history of ascites (> trace), indicating ""yes.""",`,1,0,1
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07526835].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, I predict that the main patient does *not* have a diagnosis of seizures requiring antiepileptic medications (""no""). The main patient has a complex surgical history primarily related to hypoplastic left heart syndrome, with experiences that have not indicated the presence of seizures or related neurological complications. The similar patients did not show significant trends or evidence suggesting a high likelihood of epilepsy or seizure disorders based on their surgical histories. Furthermore, the XGBoost model's estimated probability of 0.0753 strongly supports the notion that the occluded outcome (having a diagnosis of seizures) is less likely in this cohort, enhancing the confidence in the prediction of ""no.""","Based on the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model's estimated probability of 0.075, which is significantly below the threshold for indicating a positive diagnosis, strongly supports this prediction. Additionally, looking at the outcomes of similar patients, particularly those with hypoplastic remaining structures and NYC classifications, seizure diagnoses were infrequent; most did not have such a diagnosis, suggesting a trend where these complex congenital heart defects do not inherently result in seizures. Given that the main patient also has no reported history of neurological complications or cardiac arrest, this further reinforces the likelihood that they are free from seizures requiring treatment.",1,1,0
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.97162825].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the XGBoost model's prediction probability of 0.97162825, it strongly suggests that the occluded outcomeâ€”whether the patient has a history of pacemaker placementâ€”is likely ""yes."" This prediction is supported by the fact that among similar patients, particularly those with conditions such as tricuspid atresia and double outlet right ventricle which often lead to complex surgical histories, there is a notable incidence of pacemaker placements as part of their management. Furthermore, the main patient's surgical history includes interventions that can lead to arrhythmias, which often necessitate the use of a pacemaker. Given these considerations, the evidence points towards the main patient likely having had a history of pacemaker placement.","Based on the information provided, the model predicts a high probability (0.9716) that the main patient has a history of pacemaker placement. In analyzing the main patientâ€™s history, there is no mention of a pacemaker, which corresponds with several similar patients who also do not have histories of pacemaker placement. However, the high predicted probability suggests that features from the main patient and the cohort enhance the likelihood of a similar outcome arising in those with comparable or related surgical histories. The known successful outcomes in similar patients undergoing complex procedures like the Fontan indicate that pacemaker placements can sometimes be needed, albeit not frequently documented. Considering the trends and the modelâ€™s strong predictive metrics, the conclusion leans towards a likely yes for a pacemaker history, even if not explicitly documented.",1,1,1
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.19102933].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, I predict that the main patient has not died. The XGBoost model estimates a low predicted probability (0.19) of the occluded outcome, which indicates a strong likelihood that the event of death did not occur. Additionally, the main patient's medical history shows several successful surgeries, a reported status update of no significant complications, and a lack of critical findings that are often associated with mortality outcomes in similar patients. Moreover, similar patients in the dataset, including those with comparable surgical and clinical profiles, predominantly have a survival status without significant complications following their procedures. Thus, considering the model's strong performance and the trends from the similar cohort, the outcome likely reflects survival.","Based on the available data, the predicted clinical outcome for the main patient is ""no,"" they have not died. This conclusion is supported by the patient's clinical history, which includes multiple cardiac surgeries and no known serious complications like major thrombus, cardiac arrest, or significant pleural effusions that are commonly associated with higher mortality risk in similar patients. Additionally, the model's prediction probability of 0.19102933, which indicates a low likelihood of death, aligns with a general trend seen in the similar patients, most of whom have not experienced mortality post-Fontan surgery. The informative metrics from the XGBoost model further reinforce this; it has high accuracy and AUC-ROC, showing strong predictive validity in this context.",1,1,0
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01764377].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, the predicted outcome for whether the patient received a heart transplant is **no**. The XGBoost model estimates a very low probability (0.0176) for this outcome, suggesting that the majority of similar patients did not undergo transplantation. Additionally, the main patient's surgical history demonstrates a complex case of hypoplastic left heart syndrome with multiple surgeries but no indication of receiving a heart transplant or prior listing for one. Furthermore, most analogous patients also share a pattern of not receiving transplants due to their clinical conditionsâ€”showing that while they experienced significant cardiac interventions, they did not reach the point of requiring a transplant. This trend, coupled with the model's prediction and the clinical context, reinforces the expectation that the patient likely did not receive a heart transplant.","Based on the available data, the missing clinical outcome regarding whether the main patient received a heart transplant can be predicted as **""no.""**

The main patientâ€™s clinical history suggests significant complexities, including having undergone multiple surgeries related to hypoplastic left heart syndrome, without a staged bridge to transplantation. Examining the similar patients, while 67% experienced heart transplants, those with comparable conditions and surgical profiles often did not, as indicated by the lower transplantation rates in patients with more complex morphologies or conditions requiring multiple interventions without immediate prescription for transplantation. Additionally, the XGBoost model predicts a very low probability (1.76%) of transplantation for this cohort, reinforcing the inference that the main patient likely did not receive a heart transplant.",1,1,0
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9928019].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the main patient **does have a history of pacemaker placement**. This conclusion is supported by multiple factors. First, the main patient's extensive surgical history, including procedures for valve regurgitation and arrhythmias, suggests a higher likelihood for subsequent rhythm management interventions such as pacemaker placement. Additionally, among the similar patients, those who underwent multiple cardiac interventions, especially related to valve issues and arrhythmias, demonstrated a notable prevalence of pacemaker placements in their clinical histories. The high predicted probability of 0.9928 from the XGBoost modelâ€”combined with these observationsâ€”reinforces the likelihood that the main patient has also required similar intervention for arrhythmia management.","Based on the available data, it is likely that the main patient has a history of pacemaker placement. This inference is supported by the high probability estimate from the XGBoost model, which predicts a 99.28% chance that the patient has undergone this intervention. Additionally, examining the similar patients, many of whom have histories of complex surgeries and complications associated with single ventricle physiology, suggests that the need for a pacemaker may be a common outcome in this cohort, especially given the surgical history of multiple interventions and the presence of arrhythmias. Therefore, considering both the statistical evidence and the clinical trends, it is reasonable to conclude that the main patient has a history of pacemaker placement.",1,1,1
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.5020602].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided information and the data of similar patients, it is reasonable to predict that the main patient does not have a history of ascites (>trace). The main patient has a relatively stable surgical history, notably without significant complications such as the need for Fontan re-intervention, which may indicate a better prognosis. Additionally, the XGBoost model predicts a probability of 0.5020602 for the occluded outcome being ""yes,"" which is close to the decision threshold (0.5) but still not definitive. Most patients with a similar surgical history who have had some complications, such as those with Fontan revisions or a more complicated cardiac diagnosis, did report issues with ascites. Hence, it aligns that the main patient's overall clinical picture suggests they likely do not have a significant presence of ascites.","Based on the analysis of the main patient's data and the insights from similar patients, the predicted clinical outcome for the question ""Does the patient have a history of ascites (> trace)?"" is **yes**. The main patient has multiple indicators of significant cardiovascular and post-surgery complications, such as a history of renal dysfunction and elevated liver fibrosis test results, which commonly correlate with ascites. 

Furthermore, reviewing the similar patients' outcomes indicates that those with comparable surgical histories and clinical features, particularly presence of Fontan pathways, often face similar complications like ascites, especially in the context of elevated pressures and heart failure signs post-surgery. The XGBoost model prediction of a 50.2% probability aligns with these observations, suggesting that the patient is at reasonable risk for developing ascites, thus supporting the conclusion that a history of ascites is likely.",0,1,1
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00538816].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, I predict that the main patient **did not** receive a heart transplant. The XGBoost model's predicted probability of the occluded outcome being 'yes' is very low (0.0054), suggesting a negligible likelihood of the patient having undergone a transplant. 

Moreover, similar patients with comparable surgical histories (mostly involving multiple surgeries like Fontan procedures) and outcomes showed a limited occurrence of heart transplants, particularly those with complex anatomical issues like the main patient, who also displays significant comorbidities and complications relevant to heart transplantation (like ascites and elevated liver fibrosis test). This aligns with the overall trend that patients with complex congenital heart issues undergoing Fontan procedures often face a complicated clinical course without resulting in transplant eligibility.","Based on the available data, it is predicted that the main patient **did not receive a heart transplant**. The XGBoost model indicates a very low probability (0.0054) for the occluded outcome being 'yes', suggesting that the likelihood of having received a transplant is minimal. Additionally, the similar patients show a trend where few had a heart transplant, particularly those with complex surgical histories, as indicated by their various interventions but still not meeting criteria for a transplant. Given the main patient's record of multiple surgeries, including the Fontan procedure without subsequent revision or indications for a transplant, this aligns with the overall low forecast for transplant in similar clinical profiles.",1,1,0
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06291912].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the analysis of the main patient's clinical data and the insights drawn from similar patients, the likely outcome for the question of whether the patient has a diagnosis of seizures requiring antiepileptic medications is ""no."" The main patient has a history of stroke, which could suggest an increased risk for seizures, but no direct evidence of seizures is indicated. The similar patients, particularly those with higher procedural complexity and a history of cardiovascular events, show a lower prevalence of seizures despite similar surgical histories, which positions the main patient in a comparable risk category. The XGBoost model further supports this prediction, estimating a low probability (0.0629) for seizures, suggesting that the overall likelihood of this outcome is minimal in the absence of a definitive history.","Based on the provided data and the prediction from the XGBoost model, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The model's output indicates a low probability (0.0629) for the occluded outcome (seizures), which suggests that seizures are unlikely to be a significant issue in this patient's case. Furthermore, similar patients with a history of seizures often had associated risk factors such as higher rates of arrhythmias and complications post-surgery. In contrast, the main patient's surgical history includes multiple surgeries and interventions without documentation of seizures or associated antiepileptic treatments, reinforcing the prediction that seizures are not a concern for this patient.",1,1,0
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.24075049].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the given data and the predictions from the XGBoost model, it seems likely that the patient has not died. The model predicts an approximately 24% probability that the outcome ""has the patient died?"" is 'yes', which is relatively low. Additionally, the main patient has no history of serious complications leading to mortality such as major thrombus, significant arrhythmias, or the need for urgent transplant, as indicated by their stable cardiovascular function in the MRI assessment and surgical history. 

In contrast, several of the similar patients exhibited histories of complications, but the majority of them have not experienced death, which aligns with the predictive modeling outcome. The high accuracy (96%) and AUC-ROC of 0.87 reinforce confidence in interpreting the low probability as an indicator of survival for the main patient. Therefore, the reasoning suggests that the likely outcome is that the patient is alive.","Based on the available data and the XGBoost model's prediction of a 24.08% chance of the occluded outcome being 'yes,' it is likely that the main patient has not died (i.e., prediction of 'no'). The main patient exhibits a stable hemodynamic profile and a good F-function with normal ventricular mass and volumes, as indicated by their MRI report. In contrast, similar patients, who faced significant risks and challenges, often had higher mortality or severe complications leading to death, particularly those with complications following the Fontan procedure. Given the main patient's lack of severe systemic complications (e.g., no history of significant thrombus, stroke, or heart failure), it aligns with a lower probability of mortality, supported by the modelâ€™s performance metrics reflecting a strong outcome prediction for survival. Thus, the most reasoned conclusion is that the patient has not died.",1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00710511].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, the prediction for whether the main patient received a heart transplant should be ""No."" This prediction is substantiated by both the main patient's surgical history and the analysis of similar patients. The main patient has undergone multiple significant cardiac interventions, including Fontan surgery and a Stansel procedure, but there is no record of a heart transplant. 

Furthermore, reviewing the surgical histories of the similar patients, those who underwent multiple subsequent surgeries to address their congenital heart defects, like the Fontan procedure, also did not typically receive heart transplants, as they were managed with palliative surgical approaches instead. The XGBoost model predicts a low probability (0.0071) of undergoing a heart transplant, which reinforces the conclusion that transplant status is unlikely based on both clinical context and model estimates.","Based on the provided data and the XGBoost model's prediction, it is reasonable to conclude that the main patient did not receive a heart transplant. This prediction is supported by the model's calculated probability of 0.00710511â€”which indicates a very low likelihood of receiving a transplant. Additionally, looking at the similar patients, many successfully underwent multiple surgeries, including Glenn and Fontan procedures, but had no history of heart transplantation, often reflecting a strategy of managing single ventricle physiology through surgical palliations instead. The main patient's extensive surgical history, including a complicated Fontan procedure, aligns with this management strategy, suggesting a focus on optimizing existing anatomy rather than resorting to transplantation.",1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0010774].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided information, the prediction is that the main patient does **not** have a history of pacemaker placement. The main patient has a complex surgical history due to hypoplastic left heart syndrome, having undergone multiple interventions including Fontan surgery, but has no recorded history of pacemaker placement. Furthermore, similar patients with comparable surgical histories (particularly those with Fontan operations) and the general cohort trends indicate that while some did receive pacemakers, many also did not, particularly in cases without significant electrical or rhythm disturbances noted in their medical evaluations. The XGBoost model further supports this prediction by providing a very low probability (0.0010774) for the occluded outcome (""yes"" for having a pacemaker), suggesting a very strong consensus that this patient likely does not have one.","Based on the data provided, the prediction for whether the main patient has a history of pacemaker placement is **no**. The main patient has undergone multiple surgeries and interventions related to his single-ventricle physiology, particularly focusing on managing complications linked to the Fontan procedure and detailing arrhythmias such as atrial tachyarrhythmias. However, there is no mention of adverse events or significant arrhythmias postoperatively that would typically necessitate a pacemaker.

Analyzing similar patients, none of them report a history of pacemaker placement despite having undergone comparable surgeries, including Fontan and Stansel/Damus procedures. Additionally, the XGBoost model's prediction with a probability of 0.0010774â€”the closest prediction to a negative outcomeâ€”reinforces the likelihood of the main patient not having a pacemaker. The aggregated data on the surgical history and outcomes of comparable patients point toward a lower incidence of pacemaker requirements, hence supporting the prediction that the main patient has not had a pacemaker placed.",1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.1187084].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the predicted outcome for the main patient regarding the history of ascites (> trace) is **no**. The main patient has a surgical history that includes multiple significant interventions for hypoplastic left heart syndrome, but there is no indication in the clinical status updates of prior ascites, which is a notable clinical concern in post-Fontan patients. 

Moreover, examining the similar patients' data reveals that patients with comparable cardiac anomalies such as hypoplastic left heart syndrome or those who underwent complex surgical interventions like the Fontan procedure also tend to have reports indicating no history of ascites. The XGBoost model's predicted probability of 0.1187, which leans towards a 'no' classification, reflects a strong consensus against a history of ascites, aligning with the clinical histories of similar cases effectively captured by the model. Thus, taking both the individual patient data and the broader cohort trends into account leads to the conclusion that this patient likely does not have a history of ascites.","Based on the data provided, it is reasonable to predict that the main patient does not have a history of ascites (> trace). The patient's clinical history suggests significant complications related to their cardiac function, including a thrombotic occlusion of the fenestration and depressed cardiac function after Fontan surgery, which may have led to fluid overload; however, no reports of ascites are documented. 

When comparing to similar patients, particularly those who underwent comparable surgical histories, a trend emerges where the occurrence of ascites appears to be linked more to specific postoperative complications such as protein-losing enteropathy or hepatic dysfunction. Since the main patient lacks these conditions, and given the model's low predicted probability for the occluded outcome being 'yes' (0.1187), it is likely that the absence of documented symptoms or complications associated with ascites suggests they do not have a history of this condition.",1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0552157].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the main patient's surgical history and MRI findings, it is plausible that they may not have a diagnosis of seizures requiring antiepileptic medications. The absence of any documented seizures or atrial tachyarrhythmias in their current medical history, despite their extensive surgical interventions related to hypoplastic left heart syndrome, diminishes the likelihood of such a diagnosis. Furthermore, similar patients with comparable surgical histories, including those who have undergone the Fontan procedure and have developed other complications, did not show a high incidence of seizures, suggesting that while the risk exists, it may not be common. The XGBoost modelâ€™s predicted probability of 0.0552157 strongly supports this conclusion, indicating a low likelihood of the occluded outcome occurring in this patient. Thus, the prediction for the occluded outcome is **no**, the patient does not have a diagnosis of seizures requiring antiepileptic medications.","Based on the provided data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model predicts a low probability (0.0552157) of the occluded outcome occurring, which suggests that seizures are unlikely. Furthermore, the similar patients do show some instances of seizures and associated antiepileptic medication use, but these cases typically also have a significant cardiac history that differs from the main patient's outcomes. Given the overall context of the patient's clinical presentation, including ongoing monitoring without notable neurological complications, it is reasonable to conclude that seizures have not been a factor for this patient. Thus, the prediction leans towards ""no"" for the diagnosis of seizures requiring antiepileptic medications.",1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01601037].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, the predicted outcome for whether the patient has died is **""no.""** The main patient has undergone multiple complex cardiac procedures, including a successful Fontan operation, and their surgical history does not indicate any post-operative mortality. Additionally, the trends observed in similar patients, particularly those with hypoplastic left heart syndrome and comparable surgical histories, suggest a generally favorable prognosis. The XGBoost model's predicted probability of the occluded outcome being ""yes"" is very low (0.016), and the associated metrics indicate that the model is reliable, reinforcing the conclusion that this patient is likely still alive. The absence of severe complications or a significant history of life-threatening events further supports this prediction.","Based on the clinical and surgical history of the main patient, as well as the predictions from the XGBoost model, it is reasonable to predict that the patient has not died. The model estimates a very low probability (1.6%) that the occluded outcome (""Has the patient died?"") is 'yes', supported by the fact that the majority of similar patients who have undergone similar surgeries and interventions have not experienced death, as indicated by a high overall accuracy (96%) of the model and strong performance metrics. Additionally, the main patient has undergone multiple interventions and treatments indicating active health management, further suggesting less likelihood of a fatal outcome.",1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07208246].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"The prediction for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **no**. This conclusion is supported by the patient's overall clinical parameters; there is no documented history of seizures in their extensive surgical or medical history, which includes multiple cardiac procedures but no neurological complications. Additionally, the similar patients exhibited a low incidence of seizures, as indicated by the data, with most patients without such a diagnosis, and the support from the XGBoost model, which estimates only a 7.21% probability of seizure events based on the occluded outcome in this patient population. Therefore, based on the patientâ€™s history and trends among similar cases, it is reasonable to conclude that the patient likely does not have a diagnosis of seizures requiring antiepileptic medications.","Based on the data provided, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model indicates a low predicted probability (0.0721) for the occurrence of the occluded outcome, reflecting that, given the patient's surgical history and clinical parameters, the features strongly suggest absence of this diagnosis. Additionally, among similar patients who underwent similar surgeries and have cardiac diagnoses similar to the main patient, a historical prevalence of seizure diagnoses appears low, especially among those with a diagnosis of hypoplastic left heart syndrome or similar conditions, which the provided cohort represents. Therefore, considering both the modeling and the trends in outcomes from peers, it is reasonable to conclude that the patient likely does not require antiepileptic medication.",1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00099053].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, the predicted missing clinical outcome for the main patient is **no**, they did not receive a heart transplant. The XGBoost model predicts a very low probability (0.00099053) for the outcome being 'yes,' suggesting that the factors associated with being a transplant recipient are not present in this patient. Additionally, examining the similar patients, many also had histories of multiple cardiac interventions and complex single-ventricle physiology, yet few proceeded to transplantation, implying that shared characteristics lead to better management through surgeries rather than transplantation. Thus, the combination of the model's prediction and the patterns in similar patients supports that this patient likely remained managed through surgical procedures without requiring a transplant.","Based on the provided data, the predicted outcome for whether the main patient received a heart transplant is **no**. The main patient has a history of three cardiac surgeries, including a Fontan procedure, consistent with a population that often does not receive a heart transplant due to the complex nature of their congenital heart disease. Furthermore, among the similar patients, who have comparable cardiac diagnoses and histories, there is a consistent trend of not receiving heart transplants, with features such as an intact morphology and successful management through multiple surgeries. The XGBoost model's predicted probability of the occluded outcome being 'yes' (0.00099053) supports this, indicating a strong likelihood that the patient did not undergo a heart transplant; the accuracy of the model suggests confidence in this prediction.",1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00088999].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided information, the prediction for the occluded outcome of whether the patient has a history of pacemaker placement is ""no."" This conclusion is drawn from the main patient's clinical history, which shows no documented issues that typically necessitate pacemaker placement, such as significant arrhythmias or a history of cardiac arrest. Furthermore, analysis of the similar patients indicates a predominance of cases without pacemaker placement, especially among those with similar surgical histories and anatomical considerations, reinforcing the low likelihood of requiring such an intervention. The XGBoost model's estimated probability of 0.00088999 further supports this prediction, suggesting a strong confidence that the outcome did not occur.","Based on the available data, I predict that the main patient does **not** have a history of pacemaker placement. The XGBoost model estimates a very low probability (0.00088999) of the patient having a history of a pacemaker, which is well below the typical threshold for classification. 

Looking at the similar patients, particularly those with comparable surgical histories and clinical features, most did not have a history of pacemaker placement either. The patterns observed suggest that for patients who underwent an extracardiac Fontan procedure and had no significant arrhythmic events recorded in their histories (including the main patient), the need for a pacemaker is less likely. Thus, based on the combination of model prediction and historical trends in similar patients, it seems reasonable to conclude that the main patient likely does not have a history of pacemaker placement.",1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00079606].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, the prediction for the occluded outcome, ""Has the patient died?"" is **no**. The main patient has had a complicated surgical history with three cardiac surgeries, including an Extracardiac Fontan and a bidirectional Glenn, but there are no indications of significant complications, such as cardiac arrest, thrombus, or severe arrhythmias that resulted in a negative outcome. Furthermore, the XGBoost model predicts a very low probability (0.00079606) for the patient having died, supported by the model's high accuracy (0.96) and AUC-ROC (0.87) metrics, implying confidence in the model's predictions. Similarly, the similar patients indicated a trend of surviving post-surgery with no reported deaths, further reinforcing the prediction that the main patient has not died.","Based on the presented data, it is predicted that the main patient has *not died*. The XGBoost model assigns a very low probability (0.00079606) for the outcome indicating the patient has died, which is consistent with the results from similar patients who also have undergone a series of cardiac surgeries centered around the Fontan procedure. Analysis of the similar cohort suggests that many patients with comparable surgical histories and physiological metrics have a high survival rate post-surgery, particularly those without significant complications such as protein-losing enteropathy or arrhythmias, which the main patient also does not exhibit. The combined evidence from the model and observed trends in outcomes for similar cases supports the prediction of survival.",1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00930508].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"**Prediction:** No, the patient does not have a history of ascites.

**Reasoning:** The main patient has undergone multiple surgeries, including an extracardiac Fontan, but does not show any signs of complications commonly associated with ascites, such as significant reoperations or interventions specifically addressing fluid management, as indicated by their surgical history. Furthermore, the XGBoost model predicts a very low probability (0.0093) of the occluded outcome (history of ascites) for this patient, suggesting that, based on the model's assessment of similar cases, the likelihood of experiencing ascites is minimal. In the cohort of similar patients reviewed, many have reported thriving without significant complications related to ascites, particularly those with analogous surgical histories, which further supports this conclusion.","Based on the available data, I predict that the main patient does **not** have a history of ascites (> trace). The training data indicates that similar patients with a known history of Fontan surgery and a low predicted probability (0.0093) for the occluded outcome of ascites were generally not observed to develop this condition. In particular, among the similar patients, none reported a history of ascites, and given the overall characteristics sharedâ€”such as surgical history (including being a Fontan candidate with fenestration)â€”it suggests a consistent trend of low prevalence for this outcome in the cohort. The XGBoost model, with a high AUC (0.88), strongly supports this prediction, emphasizing the reliability of the findings regarding this specific clinical outcome.",1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.1640789].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the data provided for the main patient and the similar patients, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model's prediction probability of 0.164 indicates a low likelihood of seizures for the main patient, and it aligns with the low incidence of seizures observed in the similar patients who underwent various cardiac surgeries, all of which generally exhibited a lower association with seizure diagnoses in this cohort. Additionally, the main patient has a mix of notable complications, namely a history of thrombus and mild arrhythmias, but no indication of seizures, which further supports the prediction. Thus, the clinical history and model data suggest that the patient is less likely to require antiepileptic treatment.","Based on the provided patient data, the predicted outcome for the main patient is **no**; the patient does not have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model indicates a predicted probability of 0.164, suggesting a low likelihood of this outcome occurring. Additionally, the similar patients, who have undergone similar surgical interventions, show no significant history of seizures, particularly among those with comparable diagnoses and surgical histories. These factors, combined with the relatively low occurrence rate of seizures in this demographic, support the conclusion that the main patient is unlikely to have such a diagnosis.",1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.5239016].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Given the main patient's history and the insights from similar patients, the predicted outcome for the patient is **""no""** regarding the history of ascites (> trace). 

The main patient has complex surgical history but no documented evidence of ascites in their previous events or examinations. Looking at similar patients, especially those with a history of Tricuspid Atresia or who have undergone procedures like a Fontan or hybrid procedures, many have recorded ""no"" for ascites despite some having other significant comorbidities. Moreover, the XGBoost model provides a probability of 0.5239016, which is close to the boundary but leans towards not having the condition, complementing the clinical history data. Therefore, it seems unlikely this patient would have a notable history of ascites that exceeds a trace.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). The main patient has undergone several surgeries, including a lateral tunnel Fontan and multiple interventions involving veno-venous collaterals, yet has no documented cases of pleural effusions, which often accompany ascites. In comparison to similar patients, many have a history of ascites, especially those with a significant history of liver complications; however, the majority do not demonstrate ascites when there is effective management of their hemodynamics. Furthermore, the XGBoost model suggests a 52.39% probability of the occluded outcome being 'yes,' which is near the threshold but still leans toward 'no' given the overall context and trends from the similar patients observed.",0,0,1
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03200265].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"The missing clinical outcome prediction for the main patient is **no**, indicating that the patient did not receive a heart transplant. This prediction aligns with the data indicating a history of intracardiac thrombus and elevated liver fibrosis tests, which may complicate the suitability for transplant. Additionally, when comparing to similar patients, none of them received a heart transplant, and they exhibited comparable clinical and surgical histories, including a prevalence of complications such as protein-losing enteropathy and arrhythmias. The XGBoost model's predicted probability of 0.032 indicates a low likelihood of having received a transplant, suggesting that the patient may continue to be managed as a complex case of single ventricle physiology without progressing to transplant eligibility.","Based on the provided data, the prediction for whether the main patient received a heart transplant is **no**. The main patient has undergone five cardiac surgeries, including a significant surgical history involving various interventions typical for single-ventricle patients; however, there is no mention of any heart transplant, which suggests that the current treatments were deemed sufficient to manage their condition without transplanting a new heart. Moreover, examining the similar patients, the ones with comparable surgical histories, particularly noting those with tricuspid atresia and other complex morphologies, have also typically not received heart transplants unless indicated by severe complications. The XGBoost model's predicted probability of 0.03200265 reinforces this conclusion, signifying a low likelihood of having received a heart transplant, aligning well with the overall trends observed in the collected data.",1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.13145462].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the data presented, the prediction for the missing clinical outcome, ""Has the patient died?"", is **no**. The main patient has a complex surgical history with a Fontan procedure and several interventions that generally align with positive outcomes as seen in similar patients, most of whom have not experienced mortality. Although there are risk factors present, including a history of thrombus and mild arrhythmias, the XGBoost model predicts a low probability of mortality at approximately 13.15%, reflecting the overall good health management of similar patients in the cohort. Furthermore, the performance metrics of the model, which indicate high accuracy and precision in predicting outcomes, lend credibility to this prediction.","Based on the provided XGBoost model probabilities, the main patient's estimated probability of the occluded outcome (""Has the patient died?"") being 'yes' is approximately 0.131, indicating a low likelihood of mortality. This conclusion aligns with the underlying data, where the main patient exhibits a history of multiple surgeries but has not experienced significant acute complications or life-threatening conditions. Additionally, among similar patients, those who have experienced cardiac interventions and had outcomes recorded similar to the main patient's not only survived but also managed chronic conditions effectively. Overall, considering the model's accuracy and the favorable clinical history of both the main and similar patients, the prediction would be that the patient is likely alive. Thus, the informed prediction for the outcome is **""no.""**",1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00645357].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, the prediction for whether the main patient has a history of pacemaker placement is **no**. The main patient has not shown a history of atrial tachyarrhythmias, and despite the complex surgical history involving multiple interventions, there is no indication of necessary pacing support. Furthermore, similar patients with comparable surgical histories, such as those with tricuspid atresia or the dominant left morphology, did not have a history of pacemaker placement either, despite having undergone similar procedures and facing potential complications. The XGBoost model further supports this conclusion with a low predicted probability of the occluded outcome being 'yes' (0.00645357), suggesting that the likelihood of having a history of pacemaker placement is minimal.","Based on the available data, it is predicted that the main patient does not have a history of pacemaker placement. This aligns with the information from the similar patients, none of whom had a history of pacemaker placement either, despite having various forms of congenital heart defects and undergoing multiple cardiac surgeries. Additionally, the main patient's clinical status does not indicate any significant arrhythmias that would typically necessitate pacemaker intervention, as there are no records of sustained or non-sustained ventricular tachyarrhythmias, although there is a history of atrial tachyarrhythmias. The low predicted probability (0.00645357) from the XGBoost model also supports the conclusion that the occluded outcomeâ€”having a history of pacemaker placementâ€”is negative for this patient.",1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0933895].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the given data, the predicted outcome for the main patient regarding a diagnosis of seizures requiring antiepileptic medications is **no**. This conclusion is supported by the fact that none of the similar patients, despite their varied surgical histories and cardiac diagnoses, reported a history of seizures or related interventions. Additionally, the XGBoost model predicts a low probability (approximately 9.34%) for this outcome to be 'yes', indicating that the occurrence of seizures among similar patients is rare. Without any documented history of seizures in the main patient or the similar cohortâ€™s records, it is reasonable to anticipate that the main patient likely does not have this diagnosis.","Based on the provided data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model generates a comparatively low predicted probability of 0.093, suggesting a strong likelihood that the condition is absent. Additionally, among the similar patients, none demonstrated a history of seizures, particularly those who had similar surgical histories or cardiac diagnoses. Furthermore, the main patient does not present with complications commonly associated with seizure disorders, which further supports the prediction that seizures are unlikely in this case.",1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0526533].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the analysis of the main patient's data and the characteristics of similar patients, it is predicted that the main patient does **not** have a history of ascites (> trace). The main patient has undergone multiple Fontan procedures and exhibited good overall performance metrics, with no indication of ascites reported during their history. Additionally, among similar patients, particularly those with Tricuspid atresia and other congenital heart defects, the presence of ascites was often associated with adverse outcomes such as heart failure or systemic congestion, which seems to be less common in patients with successful management of their surgical histories. Given the low estimated probability of 0.0526533 from the XGBoost model, indicating that it is unlikely this outcome occurred, it further supports our prediction that the patient does not have ascites.","Given the main patient's detailed clinical and surgical history, including multiple cardiac surgeries and interventions related to their complex condition (tricuspid atresia), there is a significant likelihood that complications such as ascites could arise post-Fontan surgery. The XGBoost model predicts a low probability (0.0526533) of the occluded outcome being 'yes', suggesting a low likelihood of ascites. However, several similar patients who have undergone similar surgeries and have a history of relevant complications, including pleural effusions and ascites, which were documented in their clinical histories, suggest that such outcomes are conceivable in this patient cohort. Overall, although the model's output leans towards a negative prediction, the historical trends in patients with similar conditions indicate that there remains a possibility of ascites occurring, thus supporting a prediction of ""yes"" for the main patient's history of ascites.",1,0,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00583627].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, I predict that the main patient did NOT receive a heart transplant. The XGBoost model predicts a very low probability (0.0058) for the occluded outcome, indicating a strong likelihood that the patient did not undergo a heart transplant. Furthermore, reviewing the surgical history of similar patients reveals that most had not received transplants either, often showing chronic management strategies for their conditions, such as the absence of significant complications that would necessitate a transplant. The patient's history and characteristics reflect patterns seen in non-transplant cases, including multiple surgeries typical for patients managed conservatively within the single-ventricle cohort.","Based on the collected data and the XGBoost model's prediction of a low probability (0.00583627) suggesting that the occluded outcome, ""Did the patient receive a heart transplant?"" is unlikely to be 'yes'. The main patient has a surgical history characterized by multiple interventions related to tricuspid atresia, including a Fontan surgery and fenestration interventions, but no mention of being listed for or receiving a heart transplant. Additionally, looking at similar patients, despite some having complex surgical histories, heart transplants are relatively infrequent in patients with similar conditions unless significant post-operative complications arise, which the main patient's status report does not indicate, as he has not shown major complications like protein-losing enteropathy or stroke. Therefore, it's reasonable to predict that this patient did not receive a heart transplant.",1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0152536].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, the prediction for the missing clinical outcome â€” whether ""Has the patient died?"" â€” is ""no"". The main patient has undergone extensive surgical interventions without any major complications documented such as thrombus, significant arrhythmias, or other life-threatening conditions. Furthermore, the similar patients with a history of Fontan surgery and comparable surgical profiles exhibit a low mortality rate, particularly when there are no severe complications noted post-surgery. The XGBoost model's predicted probability of the outcome being 'yes' is only 0.0152536, which strongly suggests a low likelihood of mortality.","Based on the provided information, the predicted outcome for the main patient regarding whether they have died is ""no."" This conclusion is supported by the fact that the patient's MRI and surgical history suggest ongoing management of their condition without severe complications or clinical deterioration that would indicate an imminent risk of death. Additionally, when looking at similar patients with comparable surgical histories and clinical features, particularly those who had similar pre-Fontan interventions and absence of significant complications (e.g., no history of sustained arrhythmias or thrombus events), the majority of them continue to be alive, reinforcing the prediction that the main patient is also alive. The low predicted probability (0.0152536) from the XGBoost model further strengthens this assessment, indicating a very low likelihood of the outcome being 'yes' (i.e., the patient has died).",1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00113855].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the main patient does **not** have a history of pacemaker placement. The main patient has had a variety of previous surgeries, including the placement of a pulmonary artery band and undergoing a Stansel/Damus procedure, but no mention of cardiomyopathy or arrhythmias that would typically necessitate a pacemaker. Furthermore, similar patients who had histories of pacemaker placements often exhibited significant arrhythmias or other complications, which are not indicated in the main patientâ€™s records. Coupled with the XGBoost model's prediction probability of 0.00113855, suggesting an extremely low likelihood of the occluded outcome occurring (""yes""), it is reasonable to conclude that this patient does not have a history of pacemaker placement.","Based on the data and trends observed in the similar patients, it is predicted that the main patient **does not have a history of pacemaker placement**. The main patient has had a history of multiple surgeries, including pulmonary artery banding and a lateral tunnel Fontan, but there is no indication of pacemaker placement recorded in their clinical history. Similarly, the patients that closely resembled this one, particularly those who underwent similar types of surgeries, predominantly did not have a documented need for pacemaker placement; this includes patients with complex ventricular morphologies. Additionally, the XGBoost model provides a very low probability (0.00113855) for the occluded outcome, reinforcing the expectation that the patient likely does not have a pacemaker history, as such a need typically correlates with higher clinical concerns that don't appear to be evident here.",1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01033198].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided patient data, the predicted outcome for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is ""no."" This prediction aligns with the findings that the main patient has a history of atrial tachyarrhythmias but no documented seizures, suggesting a lower likelihood of neurological complications. Furthermore, the similar patients also demonstrate a trend where seizures are relatively infrequent among those with comparable surgical histories of Fontan procedures, as well as the XGBoost model's estimated probability of only 1.03% for the occurrence of seizures in this cohort. This low probability, coupled with the absence of seizures in the main patient's clinical history, supports the conclusion that seizures are unlikely to be a diagnosis for this patient.","Based on the information provided, the prediction for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is ""no."" The main patient has a history of atrial tachyarrhythmias, which some studies suggest can be associated with neurological events, but there is no direct evidence of seizure activity. 

Additionally, when examining the characteristics of similar patients, notably those diagnosed with tricuspid atresia or hypoplastic left heart syndrome, while some did have indications of seizures, the overwhelming majority did not report this diagnosis. The XGBoost model's prediction of only a 1.03% probability (0.01033198) for having seizures in general, alongside the validation report indicating high overall accuracy for non-seizure cases (precisely 94% of them being correctly identified), further supports the likelihood that this specific patient does not have such a diagnosis. Therefore, it can be concluded with reasonable confidence that the main patient's clinical outcome regarding seizures should be classified as ""no.""",1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02826067].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the predicted outcome for the main patient regarding the history of ascites is **no**. The patient's MRI report indicates no significant abnormalities in the cardiac structure, and they do not exhibit any of the typical complications associated with ascites, such as significant pleural effusions or liver issues, as indicated by the absence of a positive fibrosure or elevated liver fibrosis markers. 

Furthermore, the similar patients analyzed, especially those with a history of Fontan surgeries and related conditions, show a higher likelihood of developing ascites depending on postoperative complications. In this case, the XGBoost model also provides a low estimated probability (0.02826) for the occluded outcome being 'yes,' suggesting a strong confidence that the main patient likely does not have a history of ascites. The trend of improvements in surgical techniques and patient management for single-ventricle patients also supports this prediction.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace) and thus answer ""no."" The main patient has undergone two cardiac surgeries with a history of tricuspid atresia but shows no documentation of complications related to fluid accumulation post-surgery. Among similar patients, particularly those with tricuspid atresia and Fontan surgeries, there are indications of some developing ascites; however, they often had additional complications or interventions (e.g., liver fibrosis or post-operative issues) that were not noted for our main patient. The XGBoost model supports this conclusion by predicting a low probability (0.028) of the occluded outcome, consistent with the main patient's profile and the absence of related history in the similar patients.",1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01826304].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, I predict that the missing clinical outcome for the main patient is ""no,"" indicating that the patient has not died. The patient's surgical history includes multiple procedures typical for tricuspid atresia patients but without significant complications reported, such as heart transplant or a history of critical events (e.g., cardiac arrest). The predicted probability from the XGBoost model suggests a low likelihood (approximately 1.83%) that the occluded outcome (death) occurred, reinforcing the notion that the patient has a stable postoperative trajectory. Furthermore, similarities with other patients in the cohort also indicate survival despite the complexity of their conditions, suggesting that timely medical interventions have been effective.","Based on the XGBoost model's predicted probability of death being 0.01826304, there is a very low likelihood that the patient has died, suggesting that the model predicts ""no"" for the outcome. This is further supported by the clinical history of the main patient, who has undergone multiple cardiac surgeries without any significant reported complications such as cardiac arrests or thrombus, indicating that they are managing well post-surgery. Additionally, examining similar patients, we observe that most of them have also maintained favorable outcomes post-Fontan, with a notable absence of death in those who share similar surgical histories and complications. Furthermore, the high accuracy (0.96) and relatively robust AUC-ROC (0.87) of the model suggest confidence in its predictive capacity. Therefore, the preponderance of evidence points towards the conclusion that the patient has not died.",1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00105299].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the main patient does **not** have a history of pacemaker placement. The similar patients predominantly exhibit cardiac complications related to their surgical history, yet none of the similar patients had a pacemaker placement which suggests that it may be less common in this cohort. Additionally, the main patient's history does not indicate any severe dysrhythmias that would typically necessitate the implantation of a pacemaker. The XGBoost model's output, with a very low probability (0.00105299) of the occluded outcome occurring, supports the inference that this patient likely does not have a history of pacemaker placement either.","Based on the provided data, the main patient underwent Fontan surgery and has a significant history of cardiac procedures, including a Stansel/Damus procedure. Given that the patient has a history of atrial tachyarrhythmias and non-sustained ventricular tachyarrhythmias, there is a possibility that they may require a pacemaker for rhythm management, similar to some of the matched patients who had similar diagnoses and showed a higher prevalence of pacemaker placement due to similar arrhythmias.

However, the XGBoost model's predicted probability of the occluded outcome being 'yes' is very low (0.00105299), which strongly suggests that the patient does not have a history of pacemaker placement. Taken together, these insights indicate that while the patient's clinical presentation might suggest potential need, the robust predictive model implies that it is unlikely. Therefore, it is concluded that the patient likely does not have a history of pacemaker placement.",1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00545165].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, I predict that the main patient did **not** receive a heart transplant. The patient's surgical history, including two cardiac surgeries and a lateral tunnel Fontan, along with a history of atrial arrhythmias but no recorded severe complications such as protein-losing enteropathy or significant arrhythmias requiring intensive interventions, suggests a degree of stability in their condition. Additionally, among the similar patients, while there was a minority who required transplants, the overall trend indicates that many patients with similar profiles did not end up requiring heart transplantation. The XGBoost model's predicted probability of outcome being 'yes' (0.00545165) further supports this conclusion, suggesting that the likelihood of this patient having had a heart transplant is extremely low.","Based on the provided data, I predict that the main patient did not receive a heart transplant (outcome: no). The patient's surgical history indicates two prior cardiac operations: a lateral tunnel Fontan and a subaortic stenosis resection, suggesting a focus on palliative interventions rather than definitive solutions like transplantation. Additionally, the patient's significant comorbidities, including a history of atrial tachyarrhythmias and the absence of other chronic issues like protein-losing enteropathy, further indicates a level of stability. The XGBoost model's predicted probability of 0.005 suggests a very low likelihood of needing transplant, which is consistent with the outcomes observed in similar patients who have faced comparable surgical interventions and clinical factors.",1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05793077].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, the most likely prediction for the main patient regarding whether they have died is ""no."" The patient's clinical history indicates a total of five cardiac surgeries, including a successful Fontan procedure with multiple pre-Fontan interventions, and no history of serious complications like thrombus or significant arrhythmias that would typically suggest a poor prognosis. 

Moreover, the similar patients show a trend where those experiencing significant complications or mortality had factors such as advanced arrhythmias, cardiac arrests, or severe postoperative issues, which the main patient does not appear to exhibit. The XGBoost model's predicted probability of 0.05793077â€”reflecting a low likelihood of a fatal outcomeâ€”further supports this conclusion, suggesting that the patient is currently stable. Overall, these factors lead to a strong inference that the patient is alive.","Based on the provided data, the predicted clinical outcome for the main patient is ""no,"" meaning the patient has not died. The XGBoost model gives a low probability (0.05793) for death, which indicates that it strongly favors the outcome of survival. Additionally, when examining similar patients, many of whom also had complex cardiac surgeries and managed well post-Fontan with low mortality rates, we observe a trend of favorable outcomes in patients with similar characteristics, including surgical history and clinical features such as the absence of severe complications like protein-losing enteropathy or significant thrombus history. Therefore, considering the strong predictive performance of the model and the positive trends in similar patients' data, it is reasonable to conclude that the main patient is alive.",1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01177647].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the prediction from the XGBoost model, which estimates a low probability of 0.0118 for the outcome ""Did the patient receive a heart transplant?"" being 'yes', it suggests that the model strongly leans towards a 'no' prediction for this particular outcome in the main patient. Furthermore, analyzing the similarities among the cohort, many comparable patients experienced multiple cardiac surgeries but did not receive a heart transplant, likely due to their specific cardiac anatomy and related complications. Given the main patient's extensive surgical history, including initial Fontan surgery and various interventions related to their complex condition (Hypoplastic Left Heart Syndrome), combined with the clear trend shown in the similar patients, it can be reasoned that the main patient has not received a heart transplant. Thus, the predicted outcome is 'no'.","Based on the information provided, I predict that the missing clinical outcome for the main patient is ""No,"" meaning the patient did not receive a heart transplant. The patient has a complex surgical history, including multiple surgeries and interventions related to hypoplastic left heart syndrome, which suggests a chronic condition requiring ongoing management rather than a transplant. Additionally, the prediction from the XGBoost model indicates a low estimated probability (0.0118) of the outcome being ""yes"" for transplant, underscoring that among similar patients, those with comparable surgical histories and MRI findings might also have had low rates of heart transplantation. Therefore, itâ€™s reasonable to conclude that this patient likely did not receive a heart transplant based on their clinical and imaging profiles in conjunction with model predictions.",1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02474691].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided information, it is predicted that the main patient does **not** have a history of ascites (> trace). The XGBoost model gives a predicted probability of 0.0247 for the occluded outcome being 'yes', which is quite low, suggesting a strong likelihood that the outcome did not occur for this patient. Furthermore, the main patient has been described as not exhibiting signs of complications typically associated with ascites, such as pleural effusions or significant liver dysfunction, as noted in both their MRI report and surgical history. Analyzing the similar patients, none exhibited a troubling history of ascites, which reinforces the inference that the main patient likely shares this characteristic, particularly in the context of the stability shown post-Fontan operations.","Based on the information available for the main patient, they have no history of ascites, as evidenced by the clear indication stating ""history of ascites (> trace)? no."" The predicted probability from the XGBoost model for the occluded outcome being ""yes"" is 0.0247, which suggests a very low likelihood of having ascites. 

Additionally, when examining the similar patients with comparable surgical histories, many have also reported no incidents of ascites after their respective Fontan procedures. Given the main patientâ€™s low risk profile, normal assessments, and statistically significant evidence from similar cases, it is reasonable to conclude that the patient does not have a history of ascites (> trace). Thus, the predicted outcome is ""no.""",1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02611402].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the information provided, the prediction for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is likely ""no."" The XGBoost model estimates a probability of 0.026, indicating a strong inclination toward the absence of seizures in this cohort. Additionally, the main patient does not exhibit any historical indicators for seizures or neurological complications, as seen in their clinical records. 

When comparing to similar patients, many of the cases with a history of seizures and subsequent treatment with antiepileptic medications experienced complex surgical paths or significant post-surgical complications. In contrast, the main patient's surgical history and outcomes tend to align with those who did not require such interventions, further supporting a prediction of ""no"" for seizure diagnosis. Therefore, the data from both the main patient and the analysis of similar cases suggests that this patient is unlikely to have a seizure disorder requiring antiepileptic treatment.","Given the main patient's history and the patterns observed in similar patients, it is reasonable to predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. This conclusion is drawn from the patient's clinical details, which reveal no recorded history of seizures, stroke, or significant arrhythmias that might precipitate seizures, such as sustained ventricular tachycardia. Additionally, the XGBoost model's prediction probability of 0.026, which indicates a very low likelihood of the occluded outcome, reinforces the inference that seizures are unlikely in this case. Conversely, similar patients have varying histories related to seizures and antiepileptic medications, but none of the closely matched cohorts exhibit a strong association with ongoing seizure management, suggesting that the main patient is likely free from such a diagnosis.",1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00112648].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the available data, the most reasonable prediction for the missing clinical outcome, ""Does the patient have a history of pacemaker placement?"" is **""no.""** The main patient has experienced several significant surgeries and interventions related to their complex condition, including atrioventricular valve and branch pulmonary artery procedures, but there is no indication of a pacemaker placement noted in their surgical history. 

Additionally, the similar patients demonstrate a variety of outcomes; those with comparable anatomical challenges (such as the presence of severe tricuspid regurgitation, similar to the main patient) and surgical histories showed a lower incidence of pacemaker placement, particularly among those who did not report major arrhythmias. Considering that the XGBoost model predicts a very low likelihood of the occluded event (0.00112648), it further bolsters the conclusion that a history of pacemaker placement is likely absent in this main patient.","Based on the provided data, it is predicted that the main patient does **not** have a history of pacemaker placement. The patient's history includes complex cardiac surgeries typical in single-ventricle physiology, including Fontan procedures, but lacks specific mention of any arrhythmias requiring device intervention such as a pacemaker. The similar patients, while also undergoing extensive surgical interventions and having faced various complications, show a diverse set of arrhythmia management strategies, and many have not required a pacemaker. Coupled with the very low predicted probability of 0.00112648 from the XGBoost model indicating that the occluded outcome (i.e., history of pacemaker placement) is less likely to have occurred, it reinforces the inference that the main patient likely does not have this history.",1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00734286].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the data provided for the main patient and the results from the XGBoost model, the predicted outcome is that the patient **has not died** (no). The model's estimated probability of the patient having died is only 0.0073, indicating a very low likelihood of this outcome occurring. Additionally, the main patient's clinical history, including successful surgeries (3 cardiac procedures) and the absence of complications typically associated with post-surgical mortality (e.g., cardiac arrest, significant thrombus events), aligns with trends in the similar cohort, further supporting the prediction that this patient remains alive. The high accuracy of the model (96%) reinforces that this prediction should be viewed with a strong level of confidence.","**Predicted Outcome:** No, the patient has not died.

**Reasoning:** The XGBoost model predicts a very low probability (0.0073) of the occluded outcome, ""Has the patient died?"" which strongly suggests that the model anticipates the patient is alive. Additionally, the main patient exhibits a history of multiple surgeries including a successful Fontan procedure with a known fenestration, indicating a level of management and intervention that typically correlates with better survival outcomes. Similar patients in the cohort, with comparable surgical histories and clinical characteristics, have maintained greater than 90% survival rates within this longitudinal dataset, further supporting the conclusion that this patient has not died.",1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01843921].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided clinical data, it is reasonable to predict that the main patient does not have a history of ascites (> trace). The similar patients in the cohort did not exhibit a prevalence of this condition, with multiple cases documenting clear exclusion of ascites after surgeries such as the Fontan. Moreover, the main patient's clinical status indicates no significant complications like hepatic dysfunction or fluid retention often associated with ascites, and their low risk profile correlates with the low predicted probability (0.018) from the XGBoost model, which suggests that the occluded outcome is unlikely. Therefore, given the overall trends and the patientâ€™s specific details, categorizing them as 'no' for the history of ascites appears justified.","The prediction for whether the main patient has a history of ascites (> trace) is **no**. The XGBoost model indicates a very low estimated probability (0.0184) for the occurrence of the occluded outcome, suggesting that the model predicts it is unlikely that the patient has a history of ascites. 

Furthermore, examining the similar patients shows that none of them have a documented history of ascites, despite having various forms of congenital heart diseases and surgical interventions. Additionally, the patientâ€™s current clinical status indicates no complications typically associated with ascites, such as protein-losing enteropathy or significant liver issues, further supporting the prediction that they do not have a history of ascites greater than trace levels.",1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00085787].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the information provided, the predicted clinical outcome for whether the main patient received a heart transplant is likely ""No."" This conclusion is supported by the XGBoost model, which estimates a probability of 0.00085787 (indicating a very low likelihood of having received a heart transplant). 

Additionally, examining the patient's surgical history reveals that they have undergone three cardiac surgeries, including a Fontan procedure, but there is no indication of heart transplantation in their record. Furthermore, among the similar patients, a majority with comparable surgical histories (such as those with tricuspid atresia and those undergoing the Fontan procedure) did not report a heart transplant, reinforcing the expectation that the main patient likely follows a similar trajectory regarding the management of their heart condition. Thus, these elements collectively support the prediction that the patient did not receive a heart transplant.","Based on the analysis, I predict that the missing clinical outcome ""Did the patient receive a heart transplant?"" for the main patient is **no**. 

The XGBoost model provides a probability of 0.00085787 for receiving a heart transplant, indicating a very low likelihood of this outcome. Additionally, the main patientâ€™s complex surgical history involving multiple stages, particularly the Fontan procedure with a fenestration, suggests that there may have been significant anatomical or physiological challenges, which could further diminish the likelihood of a heart transplant. 

When comparing this patient with similar patients, those who did receive transplants often had a more significant clinical history that leaned towards transplantation necessity, including factors like severe heart failure symptoms or specific complications post-Fontan. With the main patient showing no evidence of such severe complications or re-interventions that would typically elevate the urgency for transplantation, the data strongly supports a prediction of â€œnoâ€ for this outcome.",1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07493094].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. Both the main patient and the similar patients presented show significant cardiac history without the diagnosis of seizures. Notably, the XGBoost model predicts a low probability (0.07493) for this outcome, which aligns with the overall trends observed in the similar patient cohort, where only minor instances of seizure history are noted. This suggests that while some patients with complex cardiac histories may experience seizures, it appears relatively uncommon in the context of the main patient's characteristics and surgical history. Thus, it is reasonable to conclude that the main patient likely does not have this diagnosis.","Based on the provided data, I would predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model provides a predicted probability of 0.0749 for the occluded outcome, indicating a low likelihood of seizures occurring in this cohort. Additionally, analyzing the similar patients, particularly those with analogous surgical histories and cardiac diagnoses (including tricuspid atresia and associated complexities), shows a trend where only a small fraction exhibited seizures post-surgery, reinforcing the prediction's validity. Thus, the evidence suggests that the main patient's risk of developing seizures is minimal.",1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00215312].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data and the XGBoost model's prediction, the missing clinical outcome for the main patient is likely **""no""**, indicating that the patient does not have a history of pacemaker placement. Key factors supporting this conclusion include the patient's surgical history, characterized by interventions such as a lateral tunnel Fontan and the absence of arrhythmias like atrial fibrillation or sustained ventricular tachycardia. Notably, similar patients who underwent similar surgical procedures and had comparable Qp/Qs ratios did not have pacemakers or the indicative arrhythmias, suggesting a pattern where a lack of serious rhythm disturbances aligns with the absence of pacemaker placement. Additionally, the model predicts a very low probability (0.00215312) of having a pacemaker, reinforcing the inference from the patient's clinical profile and similar cohort data.","Based on the provided data and the predictions from the XGBoost model, it is likely that the main patient **does not** have a history of pacemaker placement, meaning the predicted outcome is ""no."" The main patient has a medical history characterized by multiple surgeries associated with a single right ventricle but shows no indication of severe conduction issues that would necessitate a pacemaker. 

Furthermore, the analysis of similar patients, particularly those with comparable surgical histories and cardiac diagnoses, indicates that few have required pacemaker placement, especially when combined with the presence of continued atrial tachyarrhythmias or related complications. Therefore, the model's prediction wherein the probability of a â€œyesâ€ outcome is extremely low (0.00215312) further supports this reasoning, aligning with the overall data trends which suggest that pacemakers are not common in this cohort.",1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00801779].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the analysis of the main patient's surgical history and the outcomes observed in similar patients, it is reasonable to predict that the main patient did **not** receive a heart transplant. This conclusion is supported by the low probability of receiving a transplant as indicated by the XGBoost model (0.008), which strongly suggests that the outcome is negative. Additionally, similar patients with comparable surgical histories, mainly those who underwent multiple cardiac surgeries including Fontan procedures, did not appear to have received cardiac transplants, reflecting a tendency to manage their conditions through revisions and interventions rather than transplant. Overall, considering the main patientâ€™s extensive surgical history, including a prior biventricular conversion after Fontan, the clinical course appears more aligned with focusing on functional optimization rather than transitioning to transplant.","Based on the provided information, the prediction is that the main patient did not receive a heart transplant. This conclusion is supported by several factors: the patient's complex surgical history, including previous interventions such as a biventricular conversion and multiple catheterizations, suggests a focus on managing existing physiology rather than transitioning to transplantation. Additionally, looking at similar patients, particularly those with complex single-ventricle physiology and prior Fontan surgeriesâ€”such as those that experienced successful management and maintenance of their conditions without necessitating transplantâ€”indicates a common trend. The XGBoost model's prediction of a mere 0.008 probability of receiving a transplant aligns with this reasoning, reinforcing that the likelihood of transplant intervention is low for this patient profile given their medical journey thus far.",1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05004829].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the information provided, I predict that the missing clinical outcome for the main patient is â€œnoâ€; the patient does not have a history of ascites (> trace). The main patient has undergone multiple complex surgeries, including modifications of Fontan procedures and biventricular repair without any documented complications or descriptions suggesting fluid retention issues, such as ascites. Additionally, while some of the similar patients have experienced various outcomes post-surgery, they have not shown a significant prevalence of ascites, indicating that it might not be a common complication among patients with similar surgical histories. Furthermore, the XGBoost model prediction probability of 0.050 indicates a very low likelihood of ascites history, reinforcing the conclusion based on clinical data and the patient's present status.","Based on the provided data, it is predicted that the main patient does not have a history of ascites (> trace). The patient has undergone multiple complex surgeries and procedures related to a history of hypoplastic right ventricle and is currently stable without reported complications, such as significant pleural effusions or ascites at any time post-surgery. Additionally, the similar patients, particularly those who had critical surgical histories and were also closely monitored, show trends of low instances of ascites compared to the number of surgeries performed. The XGBoost model's predicted probability of the occluded outcome being 'yes' is quite low at approximately 0.05, indicating a minimal likelihood of ascites being a relevant issue in this case.",1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00267014].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"**Prediction: No, the patient does not have a history of pacemaker placement.**

The main patient's surgical history and clinical details suggest significant intervention for complex congenital heart issues, but there is no indication of a pacemaker placement. Notably, similar patients who underwent similar surgeries, including Glenn procedures and Fontan revisions, were also reported not to have a history of pacemaker placement, demonstrating a trend. Moreover, the XGBoost modelâ€™s predicted probability for the occluded outcome, stating a likelihood of 0.00267 for having a pacemaker, reinforces this inference by suggesting a strong tendency against such interventions in this cohort. Thus, evaluating all these factors collectively supports the prediction of ""no"" for the presence of a pacemaker.","Based on the information provided, it is predicted that the main patient does NOT have a history of pacemaker placement. While the patient has undergone multiple surgeries, including a biventricular conversion and Fontan procedures, the absence of complications like the need for a pacemaker is notable in their case history. Additionally, the similar patients in the cohort had varying cardiac anomalies and treatment histories, yet those with a pacemaker placement usually displayed more significant complications or arrhythmias, which are absent in the main patient's report. Given the XGBoost model's output of 0.00267014, which strongly leans towards predicting a 'no' for the occluded outcome, it reinforces the conclusion that the patient is unlikely to have had a pacemaker placement.",1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0661893].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the available data, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model indicates a low predicted probability of 0.0661893 for this outcome, suggesting that seizures are unlikely to be present. Additionally, analysis of similar patients, who often exhibit complex surgical histories and similar cardiac diagnoses, shows that many did not have a history of seizures despite undergoing multiple cardiac interventions. Since the main patient has also experienced multiple surgeries and has no documented history of seizures in their clinical data, this reinforces the prediction of no seizure diagnosis. Overall, these insights point towards a lower likelihood of seizure occurrences in this patient.","Based on the XGBoost model prediction that estimates a 6.62% probability of the patient having a diagnosis of seizures requiring antiepileptic medications, it suggests that it is unlikely that the main patient has this diagnosis. Additionally, reviewing the data from similar patients, many who had significant cardiac histories involving surgeries and anomalies similar to the main patient did not present with this diagnosis. The majority of similar patients also lacked neurological complications, further reinforcing the likelihood that the main patient also does not have this diagnosis. Therefore, it is reasonable to conclude that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications.",1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01406133].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, the predicted outcome for the main patient, regarding the question ""Has the patient died?"" is likely **no**. The XGBoost model estimates a 1.41% probability of mortality, which is low and reflects a strong confidence that the patient is alive. Additionally, a review of similar patients reveals that those with comparable surgical histories and clinical features to this patient also show low mortality rates, particularly as they have undergone biventricular conversion and Fontan surgeries successfullyâ€”both of which are associated with improved survival outcomes. Moreover, the absence of significant complications or recurrent adverse events in the main patient's clinical history supports the likelihood of continued survival following complex interventions.","Based on the provided information, I predict that the outcome for the main patient regarding the question ""Has the patient died?"" is **""no.""** The model's prediction probability of 0.014 suggests a very low likelihood that the patient has died, along with an impressive overall model accuracy of 96% and a strong AUC-ROC of 0.87. Additionally, the surgical history of the main patientâ€”with multiple surgeries and interventions successful enough to reach a state where a biventricular repair was feasibleâ€”also indicates resilience against mortality. The similar patients analyzed show no deaths, further reinforcing the likelihood that the main patient is alive.",1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00164473].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, I predict that the missing clinical outcome for the main patient is ""no,"" indicating that the patient did not receive a heart transplant. The main patient has a complex surgical history with multiple interventions such as Fontan surgery and catheterizations, which are more characteristic of patients managed conservatively for their single-ventricle physiology. Furthermore, the predicted probability from the XGBoost model (0.00164473) suggests a very low confidence that the patient would require a transplant, corroborated by the similar patients in the dataset, most of whom did not undergo transplantation after similar surgical paths. The overall trend indicates that while this cohort has a history of complex surgeries, the majority do not end up needing transplants, further supporting the conclusion that this patient likely did not receive one.","Based on the provided data, it is likely that the main patient did not receive a heart transplant (predicted outcome: **No**). The XGBoost model suggests a very low probability (0.00164473) of receiving a transplant, and its performance metrics indicate strong reliability in predicting outcomes. 

Analyzing the main patient's surgical history, it is evident that this individual has undergone multiple procedures, including a lateral tunnel Fontan, but there is no mention of being listed for a transplant or any history indicating extreme deterioration that would typically necessitate one. Moreover, examining the trends from similar patients shows that patients with prolonged survival post-Fontan, like the main patient, often avoid heart transplantation unless faced with severe and recurrent complications, which the patient does not appear to exhibit at this time. This combination of high model accuracy and the favorable surgical history underscores the prediction of ""no"" for having received a heart transplant.",1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05693256].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the available information, it is predicted that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (i.e., ""no""). The main patient's extensive surgical history, including a complex series of procedures related to tricuspid atresia and Fontan circulation, highlights ongoing cardiovascular issues rather than neurological ones. The XGBoost model indicates a low predicted probability (0.05693256) of the occluded outcome being 'yes,' suggesting that seizures are unlikely. Furthermore, none of the similar patients reported seizures, and a common trend among these patients suggests that while they have significant cardiovascular challenges, neurological complications such as seizures requiring medication are not prevalent. These factors combined point towards the absence of a seizure diagnosis in the main patient.","Based on the provided data, the prediction for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has a complex surgical history, but there is no documented diagnosis of seizures or related history. Furthermore, among the similar patients, while some had histories of neurological complications, the majority without such histories did not receive antiepileptic medications. The XGBoost model prediction of a low probability (0.05693) further supports this conclusion, indicating that the model predicts a low likelihood of seizures among patients with similar characteristics and histories. Thus, it would be reasonable to assert that the main patient likely does not require antiepileptics.",1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0012332].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Given the main patient's extensive surgical history, including multiple cardiac surgeries and arrhythmias, it is quite plausible that they may require a pacemaker for managing any resultant electrical conduction issues. The similar patient cohort shows that patients with comparable surgical profiles, particularly after Fontan procedures and those with a history of atrial tachyarrhythmias (like ectopic atrial tachycardia), often necessitate pacemaker interventions. The XGBoost model's predicted probability of 0.0012332 indicates a low likelihood of having a history of pacemaker placement; however, the clinical context suggests that, considering the patient's complexity, they might still be a candidate for such a device despite the model's prediction. Hence, I would predict ""yes,"" the patient likely has a history of pacemaker placement, reflecting their clinical complexity rather than solely relying on predictive modeling outcomes.","Based on the provided information, it is reasonable to predict that the main patient does **not** have a history of pacemaker placement. The main patient has undergone multiple surgeries, including a Fontan operation and various catheter interventions, but there is no documentation indicating (or necessitating) a pacemaker or defibrillator placement in their history. 

When examining the similar patients, most of whom have undergone comparable surgical history (including Fontan surgeries and interventions like Glenn procedures), the trend suggests that pacemaker placements are often linked to more complex heart function issues or arrhythmias; the absence of such documentation in the main patient's history alongside the XGBoost model's prediction probability of **0.0012332** strongly suggests that the occluded outcome, which is the history of pacemaker placement, is not applicable in this case. Given the model's high accuracy and AUC-ROC performance, this further reinforces the reliability of this prediction.",0,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03090512].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the information provided, I predict that the main patient does not have a history of ascites (> trace). The main patient's reports indicate no history of liver dysfunction, pleural effusions, or protein-losing enteropathy, which are often associated with ascites. Additionally, the similar patients exhibited a pattern where those with complications such as significant valve regurgitation or marked heart failure symptoms often experienced ascites, whereas the similar patients without these conditions did not report ascites either. Given the low predicted probability of 0.0309 from the XGBoost model reinforces this, suggesting that the likelihood of the occlusion pertained to an ascites history is minimal. Overall, these trends suggest that ascites is unlikely for this patient at this time.","Based on the provided information, I predict that the main patient **does not have a history of ascites (> trace)**. The patient's MRI and surgical history indicate multiple interventions and a complex cardiac condition, but there are no noted complications relating to ascites in their current or past medical records. Additionally, similar patients, primarily those who also underwent the Fontan operation and had a history of significant cardiac surgeries, did not report ascites, even with various complications. The XGBoost model's predicted probability of the occluded outcome being 'yes' is low (0.0309), reinforcing the suggestion that ascites is unlikely in this case.",1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00904842].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, it is predicted that the main patient has not died (the outcome is ""no""). The main patient has a complex surgical history characteristic of those with single-ventricle physiology, including multiple surgeries and catheterizations without indications of profound deterioration in the latest imaging reports or events suggestive of imminent mortality. Additionally, the similar patients, many of whom also underwent complicated surgical interventions relevant to the Fontan procedure, have shown that a significant portion is alive with stable conditions despite the complexities of their cardiac issues. The prediction from the XGBoost model, which provides a low probability of mortality at 0.009, supports the conclusion that the patient is likely alive. Hence, the evidence collectively indicates that the risk of death in this case is minimal, leading to the conclusion of ""no.""","Based on the provided data for the main patient, who has undergone multiple cardiac surgeries including a Lateral tunnel Fontan and has a history of significant arrhythmias, the predicted outcome regarding mortality is **""no.""** Despite the complexity of his condition, he has not experienced cardiac arrest or required a heart transplant, which are significant indicators of mortality risk. 

Moreover, the XGBoost model predicts a very low probability of the occluded outcome (death) occurring (0.009), indicating that the model strongly suggests survival based on multiple clinical features and surgical histories within the patient cohort. Furthermore, examining similar patients with typically complicated surgical histories and interventions (such as those with tricuspid atresia and those that underwent Fontan procedures) also leans toward a sustained postoperative status rather than mortality, providing additional confidence in predicting survival in this case.",1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00420892].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, the predicted outcome for the main patient regarding whether they have died is **""no.""** This conclusion is supported by the patientâ€™s surgical history and current hemodynamic data, which suggest that despite a complex clinical backgroundâ€”including prior interventions like Fontan surgeryâ€”the patient does not exhibit significant complications like severe arrhythmias or heart failure-related symptoms that might indicate imminent mortality. Additionally, the similar patients show trends of survival despite their similar surgical histories, particularly in cases like hypoplastic left heart syndrome and double outlet right ventricle, where outcomes were not uniformly fatal. Finally, the XGBoost model's low predicted probability (0.0042) of the outcome being 'yes' strongly indicates that death is not expected in this case, further solidifying the prediction of ""no.""","Based on the information provided, the predicted clinical outcome for the main patient, ""Has the patient died?"", is **no**. The XGBoost model estimates a very low probability (0.0042) of the occluded outcome being 'yes,' which indicates a high likelihood of survival. Additionally, the similar cohort of patients reveals a trend where most have survived and do not exhibit significant risk factors leading to mortality; notably, the majority have stable cardiovascular statuses, such as low rates of complications and a lack of critical interventions in their histories. These patterns strongly suggest that the main patient's prognosis is similarly favorable, and thus the expectation is that he has not died.",1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02400114].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the available data for the main patient, including surgical history and MRI evaluations, as well as the XGBoost model prediction, it's reasonable to predict that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model estimates a very low probability (0.024) of the occluded outcome being 'yes,' which indicates that seizures are likely not a concern for this patient. Furthermore, among similar patients, those with more pronounced complications, such as history of seizures or use of antiepileptic medications, were coincidentally linked to poorer clinical outcomes, and the main patient's relatively stable hemodynamics and absence of other concerning factors further support the prediction that seizures are not present.","I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (no). The XGBoost model indicates a low predicted probability (0.024), suggesting that the occluded outcome is unlikely. Additionally, analysis of similar patients shows a relatively low prevalence of seizure diagnoses, particularly among those with a history of similar surgeries or conditions, such as those who have undergone Fontan surgery. Furthermore, the main patient's history of atrial tachyarrhythmias and usage of beta blockers may suggest a more extensive cardiac focus rather than neurological issues, reinforcing the likelihood that seizures are not a concern for this patient.",1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00092633].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, the prediction for the missing clinical outcome, ""Does the patient have a history of pacemaker placement?"", is **no**. Despite the presence of notable medical complexities, including a history of arrhythmias and prior cardioversion in the main patient, there is no documented history of pacemaker placement. 

Analyzing the outcomes of the similar patients, none exhibited a significant prevalence of pacemaker placements despite having complex cardiac histories and Fontan procedures. The XGBoost model's low predicted probability (0.00092633) for the target outcome suggests that patients like the main one, with similar MRI and surgical histories, are unlikely to have undergone pacemaker placement. Therefore, we would reasonably conclude that this patient does not have a history of pacemaker placement.","Based on the available data, it is likely that the main patient **does not have a history of pacemaker placement**. The patient's MRI report indicates stable hemodynamics with a single ventricle ejection fraction of 50.14%, which suggests sufficient cardiac function post-Fontan. Additionally, none of the similar patients, who also share a history of complex congenital heart defects (including some with more critical conditions like hypoplastic left heart syndrome), show any correlation with the need for a pacemaker despite complex surgical histories. Furthermore, the XGBoost model predicts a very low probability (0.00092633) of the occluded outcome (which includes determining if a pacemaker is needed), reinforcing the idea that this patient likely does not have a history of pacemaker placement since the overall clinical outcomes indicate relatively stable conditions comparable to the main patient's post-surgical scenario.",1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00159513].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, the predicted clinical outcome for the main patient, regarding whether they received a heart transplant, is **""no.""** 

The main patient has a history of a single cardiac surgery, which was a modified Fontan procedure, and subsequently presents with significant functional parameters such as a systemic saturation of 65% and a Qp/Qs of 1. Despite having complications from the Fontan surgery, there are no indicators of escalating conditions that typically necessitate a heart transplant, such as severe heart failure or a declining cardiac index, which could be inferred from their relatively stable current hemodynamics. 

Moreover, the similar patients, primarily with hypoplastic left heart syndrome, exhibit a greater tendency toward heart transplantation than the specific profile of the main patient, who does not show the same level of anatomical complexity or risk factors associated with transplant candidacy. These trends, combined with the XGBoost model's prediction, which gives a very low probability (0.0016) of the outcome being ""yes"" for a heart transplant, support a conclusion that the main patient likely has not received a heart transplant.","Based on the provided data, it is reasonable to predict that the main patient did **not** receive a heart transplant. The XGBoost model's predicted probability of the occluded outcome being 'yes' is notably low at 0.0016, indicating a strong likelihood of 'no'. Additionally, examining the surgical history of similar patients, those with comparable conditions, including interrupted inferior vena cava and complex Fontan surgeries, did not trend towards requiring heart transplantation, as evidenced by a lack of transplant history in similar cohorts. With the main patient's extensive history of cardiac surgeries and ongoing cardiac conditions like atrial tachyarrhythmias, this supports the notion that they have not reached a point necessitating a heart transplant given that no prior history or necessity for it has been indicated in their clinical narrative.",1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.12282468].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the predicted outcome for the main patient regarding the history of ascites is **no**. The main patient shows no documented history of ascites, pleural effusions, or significant complications associated with Fontan surgery, which usually lead to such conditions. Additionally, reviewing the similar patients, many have a history of various forms of ascites, but the closest patient with a documented complication related to ascites also has a history of extensive surgical interventions and genetic conditions, which may not directly apply to the main patient. Given the low predicted probability of 0.1228 from the XGBoost model, it is likely that the main patient does not have a history of ascites, further supported by the absence of significant comorbidities that typically lead to fluid accumulation.","Based on the analysis of the main patient's data and the similar patients' characteristics, it is reasonable to predict that the main patient does not have a history of ascites (> trace). The main patient has a recorded history free from significant post-surgical complications and has shown stable hemodynamics with saturation levels reported as acceptable. 

In the cohort of similar patients, only a few reported symptoms of ascites, particularly those who experienced more significant complications related to their surgeries, such as frequent arrhythmias and a history of multiple interventions. The XGBoost model predictively suggests a low probability (0.1228) for the occluded outcome (history of ascites), strengthening the inference that the absence of such complications is more aligned with the main patient's clinical presentation. Hence, the best judgment would be that the patient does not have a history of ascites, suggesting stable post-operative recovery.",1,1,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00370407].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the main patient's clinical data, it is apparent that they have undergone multiple significant cardiac surgeries, including atrioventricular valve procedures. However, they do not have a documented history of pacemaker placement, which suggests they have been relatively stable post-surgery. 

Looking at the similar patients, none reported a history of pacemaker placement either, despite comparable surgical histories and a similar diagnosis of Hypoplastic Left Heart Syndrome (HLHS). The XGBoost model prediction, with a low probability of 0.0037 for the occluded outcome, further supports the conclusion that it is unlikely for this patient to have a history of pacemaker placement. Therefore, the predicted outcome is **""no,""** indicating that the patient does not have a history of pacemaker placement.","Based on the provided information, it is predicted that the main patient does not have a history of pacemaker placement. Although the main patient has undergone multiple surgeries related to hypoplastic left heart syndrome, their MRI report shows no significant arrhythmias or complications that would usually warrant such an intervention. Analysis of similar patients indicates that while many have experienced various complications, those with significant arrhythmias or systemic issues related to their surgeries tend to have more interventions, including pacemaker placements. Given that this main patient has not exhibited these kinds of complications and considering the XGBoost model's prediction of a very low probability (0.00370407) of having a pacemaker history, it is reasonable to conclude that they are unlikely to have had a pacemaker placed.",1,1,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.23069319].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the information provided, I predict that the occluded clinical outcome for the main patientâ€”whether they have a history of ascites (> trace)â€”is **no**. The main patient has a positive fibrosure or significantly elevated liver fibrosis test, which indicates potential liver dysfunction but is not necessarily indicative of ascites. Additionally, all similar patients, despite having a history of elevated liver fibrosis and other complications, did not report having ascites, suggesting that the presence of elevated liver fibrosis does not universally correlate with the development of ascites. The XGBoost model's prediction probability of 0.2307 indicates a relatively low likelihood of the outcome occurring, reinforcing this assumption that the history of ascites is unlikely for the main patient.","Based on the provided data for the main patient, including their surgical history and MRI findings, it is reasonable to predict that the patient does not have a history of ascites (> trace). The main patient has not experienced any significant complications post-Fontan surgery, such as protein-losing enteropathy, which is often associated with ascites. Additionally, the similar patients' outcomes indicate that while some did report elevated liver fibrosis tests and had histories of significant complications, the majority did not present with ascites. Correlating with the XGBoost model's prediction probability of 0.23069319 (indicating a low likelihood of history of ascites), it strongly supports the conclusion that the main patient is also unlikely to have had ascites, making it more probable to answer ""no.""",0,0,1
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06353018].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the available data, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model predicts a low probability (0.06353018) for the occurrence of this outcome, suggesting that seizures are unlikely in this cohort. Additionally, similar patients with a history of complex congenital heart disease, such as Hypoplastic Left Heart Syndrome, have a relatively low incidence of seizures. Among the similar patients analyzed, only a minority have reported seizures or related conditions, indicating a trend that aligns with the main patientâ€™s clinical profile. Thus, it is reasonable to conclude that the main patient likely does not have this diagnosis.","Based on the data provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model estimates a low probability (0.0635) for the occluded outcome being 'yes,' which indicates a strong likelihood that the diagnosis of seizures does not apply to this case. Additionally, examining the similar patient cohort, none of the patients exhibited a history of seizures, while most had positive outcomes for other significant health issues. This consistency across the cohort, combined with the model's prediction, supports the conclusion that the main patient likely does not have seizures requiring treatment.",1,1,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.6036864].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the XGBoost model's predicted probability of 0.6037 for the occluded outcome being 'yes', there is a moderate likelihood that the patient received a heart transplant. Additionally, examining the data from similar patients reveals that those with comparable surgical histories and clinical presentations (e.g., similar cardiac diagnoses and surgical interventions) often had varying outcomes post-Fontan. Notably, several of these patients did not end up receiving transplants, while others had significant complications, including elevated liver fibrosis markers and histories of thrombosis. Given these observations, the possibility of the main patient receiving a heart transplant appears plausible but isn't strongly supported, leading to a prediction of **no** for this outcome, as their circumstances seem to diverge from those leading to transplantation in the cohort analyzed.","Based on the given data, the predicted outcome for the main patient is **""no,""** meaning it is unlikely that the patient received a heart transplant. The patient has a reported history of three cardiac surgeries related to Hypoplastic Left Heart Syndrome (HLHS), with multiple complex interventions performed, including a lateral tunnel Fontan and various other options that did not require transplant interventions. 

When reviewing similar patients, many demonstrate comparable surgical histories and diagnoses but have not received heart transplants either, particularly those with similar hemodynamics and outcomes post-Fontan surgery. Furthermore, the XGBoost model's predicted probability of 0.6036864 indicates a slight inclination toward the possibility of a transplant, but given its validation performance metrics and that many of the similar patients did not receive transplants, the overall trend suggests that the patient likely did not undergo a heart transplant.",1,1,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.6600426].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, the predicted outcome for the main patient regarding whether they have died is ""no."" The main patient has undergone multiple cardiac surgeries and has significant clinical and surgical history indicative of managing hypoplastic left heart syndrome. The presence of a fenestration and involvement in a proactive management strategy through staged surgeries suggests some level of stability in their condition.

Analyzing similar patients shows that a considerable number have survived despite having undergone similar procedures, with some exhibiting higher-risk features. Notably, the XGBoost model predicts a 66% probability that the occluded outcome (death) is not present. Coupled with the clinical histories revealing no instances of death among similar profiles, it supports a conclusion that the main patient is likely alive.","Based on the data provided, the main patient's predicted probability of dying post-surgery is approximately 0.66, indicating a moderately high risk. The patient's clinical history shows multiple surgeries related to complex congenital heart disease (Hypoplastic left heart syndrome, Fontan surgery with fenestration, and other interventions), including a history of cardiac thrombus, elevated liver fibrosis, and ascites, which all suggest a predisposition to complications. 

Furthermore, the similar patients also present with high-risk parameters, such as similar diagnoses, surgical histories, and outcomes affecting survival. The machine learning model indicates that while the majority of similar patients did not experience mortality (high accuracy of 0.96), those who did often had similar complications as the main patient. Therefore, considering both the model's prediction and the clinical context, it's reasoned that thereâ€™s a notable risk that the main patient has died post-surgery. Hence, the predicted clinical outcome is **yes**, the patient has died.",1,0,0
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03586051].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,"[' Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. \n Has the patient died? yes\n If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest\n']","The predicted outcome for the main patient is **""No, the patient has not died.""** 

This prediction is supported by the XGBoost model's probability assessment of 0.0359, indicating a low likelihood of the occluded outcome (death) occurring. Additionally, the main patient's extensive surgical history, including multiple interventions and the absence of critical complications such as cardiac arrest or significant arrhythmias, suggests a well-managed long-term survival. When considering the similar patients, none of them exhibited indicators that directly correlate with mortality, and the overall trends show that, despite various challenges, survival rates remain high among patients with complex congenital heart disease who have undergone Fontan procedures, particularly when adequately monitored and treated.","Based on the provided data, the predicted probability of the occluded outcome indicating whether the patient has died is approximately 0.03586, which suggests a low likelihood of death. The clinical history of the main patient shows resilience with a long surgical history involving multiple stages of complex cardiac interventions, including Fontan surgery without significant revisions. Furthermore, similar patients with comparable surgical profiles also reflected low mortality rates, with none of the similar patients reported having died. Given this combination of low predicted probability, robust surgical history, and supportive trends in similar patients, it is reasonable to conclude that the patient is likely alive at this time. Thus, the prediction for the missing clinical outcome is: **No, the patient has not died.**",0,0,1
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00107643].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"The predicted clinical outcome for the main patient regarding whether they have a history of pacemaker placement is **no**. This conclusion is supported by the main patientâ€™s extensive surgical history, which highlights significant cardiac interventions but does not mention any pacemaker placement. Moreover, in the two most similar patientsâ€”both of whom had complex congenital heart defects and significant interventionsâ€”neither was noted to have undergone a pacemaker placement. Given the XGBoost model's predicted probability of 0.00107643 for the outcome being 'yes,' and the outcomes in similar patients, it suggests that a history of pacemaker placement is unlikely for the main patient.","The main patient has undergone a total of seven cardiac surgeries, including several complex interventions such as pulmonary artery banding and a modified Fontan procedure, indicating a challenging clinical history that often correlates with more severe outcomes and complications. The model's prediction of the occluded outcome's probability being 0.00107643 suggests a very low likelihood of experiencing this specific history, which aligns with the fact that similar patients who underwent multiple surgeries typically have higher incidences of complications, including the need for pacemaker placement. 

Moreover, the absence of a known history of arrhythmia or indications of requiring a pacemaker supports this conclusion. In conjunction, none of the similar patients showed a significant prevalence of pacemaker usage, suggesting that while they faced multiple surgical interventions, it did not always lead to permanent pacing requirements. Therefore, considering these factors, it is reasonable to predict that the main patient does **not** have a history of pacemaker placement.",1,1,0
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.19984475].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the available data, I predict that the main patient does **not** have a history of ascites (> trace). The main patient has undergone multiple cardiac surgeries due to tricuspid atresia and has exhibited a complex postoperative history; however, there are no documented signs of ascites in their record. 

In contrast, from the similar patients, those with documented histories of ascites often exhibit complications related to the Fontan procedure or other forms of hemodynamic instability, which align with associated clinical factors such as elevated venous pressures or complications from procedures. The XGBoost model also predicts a low probability (0.1998) of the occluded outcome being positive, supporting the inference that ascites likely isn't a concern for the main patientâ€™s surgical history or clinical presentations.","Based on the provided data and trends from similar patients, it is reasonable to predict that **the main patient has a history of ascites (> trace), i.e., 'yes'**. The main patient has undergone multiple cardiac surgeries, including a modified Fontan, which is often associated with a greater risk of developing complications such as protein-losing enteropathy and ascites due to systemic congestion. Moreover, similar patients with comparable surgical histories and cardiac diagnoses, such as Double Inlet Left Ventricle or Atrioventricular Canal Defect, have exhibited a history of ascites. Finally, given the XGBoost model's predicted probability of approximately 20% for the outcome being 'yes', this aligns with historical trends where many patients with extensive Fontan histories develop such complications.",0,1,1
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06891212].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided information, it is most likely that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. While the XGBoost model predicts a low probability (0.0689) of the occluded outcome being 'yes,' which aligns with its classification performance indicating a low recall (0.07) for patients with seizures, the similar patients do not exhibit a significant history of seizures or related diagnoses. Furthermore, the main patient's cardiac history and existing medical conditions emphasize the absence of neurological complications, such as seizures, which supports this prediction. Overall, the combination of low predicted probability from the model and consistent patterns among similar cases leads to the conclusion that seizures are unlikely to be present in this patient.","Based on the data provided for the main patient, we predict that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The prediction aligns with the low probability estimate of 0.0689 from the XGBoost model, indicating a strong likelihood that seizures did not occur. Furthermore, while similar patients show a variety of surgical histories and comorbidities, the absence of significant arrhythmias or seizure-related history in the main patient, along with the profiles of matched patients who predominantly do not report seizures (46 cases vs 665 without), supports this conclusion. Thus, considering both the clinical data and the predictions from the model, a ""no"" is justified.",1,1,0
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.04131616].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the clinical history of the main patient, they have a complex cardiac history including multiple surgeries and a diagnosis of tricuspid atresia, which is associated with significant morbidity and a higher likelihood of complications, potentially influencing the decision for a heart transplant. The XGBoost model's predicted probability of the occluded outcome (receiving a heart transplant) is 0.04131616, indicating a low likelihood of having undergone this procedure. Additionally, similar patients in the cohort have varied outcomes, but many have not received transplants and showed a history of mortality related to cardiac complications rather than transplant outcomes, suggesting that the main patient's medical trajectory may align more closely with those who have not received a transplant. Therefore, it is reasonable to conclude that the main patient likely did not receive a heart transplant.","Based on the data provided, the predicted answer regarding whether the main patient received a heart transplant is **No**. The main patient's complex surgery historyâ€”including seven cardiac surgeries and specifically a modified Fontan procedure, without any indications of heart transplantationâ€”suggests a reliance on surgical interventions rather than transplantation. Additionally, among the similar patients, none of those with comparable surgical histories received a heart transplant; they were managed with multiple pre-Fontan interventions, akin to the main patient's extensive surgical approach. Furthermore, the low predicted probability of 4.13% from the XGBoost model reinforces the notion that heart transplantation is unlikely in this context.",1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03295961].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided information, I would predict that the main patient does **not** have a history of ascites (> trace). The patient has undergone multiple cardiac procedures, including the Fontan surgery, but there is no documentation indicating the presence of ascites. In looking at similar patients, although some experienced complications related to their clinical histories, such as aortic atresia or pulmonary artery issues, none of the similar cases indicated a significant history of ascites. The XGBoost model's predicted probability of the occluded outcome being 'yes' is quite low at 3.3%. Combined with the clinical context and surgical histories of similar patients, this supports the conclusion that the main patient likely does not have a history of ascites.","Based on the provided information, I predict that the main patient does **not** have a history of ascites (> trace). The main patient's extensive surgical history, particularly with procedures intended to address congenital heart defects, suggests a relatively stable clinical status post-surgery; additional complications like ascites are often associated with significant residual hemodynamic issues or liver dysfunction, which this patient does not appear to exhibit. Moreover, among similar patients with a diagnosis of hypoplastic left heart syndrome (HLHS) who underwent comparable interventions, there is no notable report of ascites, indicating a potential trend. The XGBoost model's low predicted probability (0.0329) further supports this inference, suggesting that ascites is unlikely in this cohort.",1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07443175].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, it is predicted that the main patient does **not have a diagnosis of seizures requiring antiepileptic medications**. The XGBoost model predicts a low probability (0.0744) for the occluded outcome being 'yes', which suggests that seizures are not a common outcome in the cohort involved. Additionally, examining the similar patients, none have a recorded history of seizures, even those with comparable surgical histories and diagnoses, indicating a trend that supports the likelihood of the main patient also being seizure-free. This aligns with the main patient's comprehensive surgical history and the absence of reported neurological issues, further weakening the probability of such a diagnosis.","Based on the provided information, the prediction for the main patient regarding a diagnosis of seizures requiring antiepileptic medications is likely **no**. The XGBoost model predicts a low probability (0.074) for the occurrence of the diagnosis, indicating a strong inclination towards ""no."" Furthermore, reviewing the surgical histories of similar patients indicates that none of them had reported a diagnosis of seizures, particularly patients with comparable conditions, such as Hypoplastic Left Heart Syndrome and associated surgical histories. Given these observations and the performance metrics of the model, it suggests that the main patient is unlikely to have a diagnosis of seizures requiring antiepileptic medications.",1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00093131].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the analysis of the main patient and the similar patients, the predicted clinical outcome is **No**, indicating that the patient did not receive a heart transplant. This conclusion is supported by the XGBoost model's output, which provides a low predicted probability (0.00093131) of the outcome being 'yes'. Furthermore, a review of similar patients, particularly those with comparable clinical histories and surgical interventions, reveals a tendency among those who did receive heart transplants to have markedly different clinical trajectories, including more severe complications or multiple surgeries. The main patient's extensive surgical history and consistent management suggest a focus on maintaining the Fontan pathway rather than transitioning to transplant, further corroborating the prediction.","Based on the provided data, the prediction for the occluded outcome, ""Did the patient receive a heart transplant?"" is ""no."" The main patient has a history of complex interventions characteristic of Hypoplastic Left Heart Syndrome, including multiple surgeries and a lateral tunneled fenestrated Fontan procedure. The XGBoost model's prediction of 0.00093131 strongly suggests that the model predicts the absence of heart transplant, supported by a high accuracy and AUC-ROC, indicating good performance in distinguishing outcomes. Additionally, trends from similar patientsâ€”many of whom have complex cardiac conditions but have not received transplantsâ€”reinforce the likelihood that this patient has not undergone such a procedure, given the overall patterns seen in the surgical histories of comparable cases.",1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03895076].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, the prediction for the main patient regarding the outcome of whether they have died is **no**. The patient's surgical history indicates that they have undergone multiple complex interventions, including a lateral tunneled fenestrated Fontan, and there are no critical indicators of acute clinical deterioration. Additionally, the similar patients, particularly those with hypoplastic left heart syndrome and related congenital heart conditions, demonstrated low mortality rates in their cohort, suggesting resilience in managing complex cases. Furthermore, the XGBoost model predicts a very low probability of the occluded outcome occurring (0.0389), lending further support to the likelihood that this patient has not died.","Based on the provided data, the predicted probability of the occluded outcome, ""Has the patient died?"", is approximately 0.03895, which is very low and suggests that the model predicts the patient has not died. This aligns with the surgical history and clinical profile of the main patient, who has undergone multiple surgeries, including a lateral tunnel Fontan without any indication of severe complications that would typically lead to mortality. Additionally, similar patients with comparable clinical and surgical histories, especially those with similar outcomes post-Fontan surgery, have not shown high mortality rates, further supporting the prediction that this patient is likely alive. Therefore, the conclusion is that the patient has not died.",1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00080105].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"**Prediction: No, the patient does not have a history of pacemaker placement.**

Reasoning: The main patient has undergone several surgical interventions for hypoplastic left heart syndrome, but there is no documentation indicating a pacemaker was utilized. Compared to the similar patients, none of them had a history of pacemaker placement either. Furthermore, the XGBoost model's predicted probability of the occluded outcome being 'yes' is quite low (0.00080105), reinforcing the inference that a history of pacemaker placement is unlikely for this patient, especially given the absence of significant arrhythmias or documented interventions that might necessitate such a device.","Based on the provided data, the predicted outcome for whether the main patient has a history of pacemaker placement is ""no."" The main patient has undergone several interventional procedures, including fenestration and various catheterizations, but there is no direct mention of pacemaker placement in their surgical history. Additionally, similar patients (all with conditions like hypoplastic left heart syndrome or similar structural heart issues) show a trend of not requiring pacemaker placements, especially considering that they also underwent similar types of surgeries as the main patient. The XGBoost model's predicted probability of the occluded outcome being 'yes', which is quite low (0.00080105), further supports the conclusion that it is unlikely this patient has a history of pacemaker placement.",1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00752685].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"The predicted probability of the main patient dying is very low at 0.0075, which strongly indicates that the occluded outcome is ""no,"" meaning the patient has not died. Looking at the main patient's surgical history, they have undergone two cardiac surgeries with no major complications reported, and their MRI evaluation shows reasonable function of the single ventricle, evidenced by a single ventricle ejection fraction close to 0.51. Additionally, the similar patients, despite having complex pathologies and multiple surgeries, have not reported significant mortality, suggesting that positive surgical outcomes can often lead to a favorable prognosis. Therefore, given the low probability from the XGBoost model and the clinical information presented, it is likely that the main patient has not died.","Based on the provided data, I predict the missing clinical outcome of the main patient is **no**, they have not died. The main patient exhibits a moderately functioning cardiac system as indicated by their MRI results, with normal flow rates and no significant obstructions or structural anomalies that would typically lead to mortality. Additionally, similar patients with comparable backgrounds (including surgical history and diagnosis of single-ventricle physiology) show a predominantly favorable survival rate, despite some experiencing complications such as protein-losing enteropathy. The low predicted probability of death (0.0075) from the XGBoost model, along with the patientâ€™s good clinical indicators and trends observed in similar patients, supports this conclusion.",1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01098996].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the data provided, I predict that the main patient does **not** have a history of ascites. The patient's clinical information shows no mention of ascites, and the known outcomes for similar patients indicated that none had significant ascitic complications following their surgeries. Furthermore, the XGBoost model's prediction probability of 0.01098996 suggests that the likelihood of the occluded outcome (history of ascites) is very low, which aligns with both the clinical characteristics and the model's performance metrics, indicating that complications such as ascites in similar cases have been relatively infrequent. This combination of factors strongly supports the prediction that the main patient does not have a history of ascites.","Based on the provided data, the main patient has no history of ascites (> trace), supported by their clinical history stating no such symptoms were recorded. Additionally, the XGBoost model predicts a very low probability (0.01098996) for the occluded outcome being ""yes"" (i.e., a history of ascites). This low probability, combined with the strong accuracy (0.93) and AUC-ROC (0.88) metrics of the model, indicates that it is very unlikely this patient has a history of ascites. Furthermore, examining the surgical histories and clinical outcomes of similar patients reveals no significant trends suggesting a higher likelihood of ascites for patients with comparable profiles, reinforcing the prediction that the main patient likely does not have this condition. Thus, I predict the missing clinical outcome is ""no.""",1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0008895].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the available data, the prediction for the missing clinical outcomeâ€”whether the patient received a heart transplantâ€”would likely be ""no."" The main patient, with tricuspid atresia and having undergone two cardiac surgeries leading to a Lateral Tunnel Fontan, does not exhibit any of the complications often associated with heart transplant candidates, such as increased systemic vascular resistance, severe ventricular dysfunction, or significant arrhythmias. 

When comparing to similar patients, though some have undergone multiple surgeries that could lead to heart transplant considerations, there is a notable cohort that shares similar surgical histories and heart conditions who did not undergo a transplant. The XGBoost model's predicted probability of 0.0008895 indicates a strong likelihood that the event did not occur, reinforcing the conclusion that the patient likely did not receive a heart transplant.","Based on the data provided, I predict that the main patient did not receive a heart transplant. The patient's surgical history indicates they have undergone Fontan surgery and have a known diagnosis of tricuspid atresia. Among similar patients, many with a comparable profile of complex congenital heart disease and prior surgical interventions have also not received heart transplants, particularly those with a history indicating successful management of their condition without such a drastic intervention. Additionally, the XGBoost model's prediction of a low probability (0.0008895) of the occluded outcome being ""yes"" strongly supports the conclusion that a heart transplant was not required in this case.",1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00071394].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, the prediction for the missing clinical outcome regarding whether the patient has a history of pacemaker placement is **no**. The main patient, who has undergone an initial Lateral tunnel Fontan surgery with a history of a fenestration, does not exhibit additional complications typically associated with the need for a pacemaker, such as significant arrhythmias or heart block. 

Moreover, when analyzing the similar patients who also underwent Fontan surgeries, none reported having a pacemaker placed, despite similar surgical complexities and conditions, further reinforcing this prediction. Additionally, the XGBoost model's predicted probability of 0.00071394 suggests an extremely low likelihood of such an occurrence, aligning with the absence of significant arrhythmias or related complications in this cohort of similar patients.","Based on the information provided, it is predicted that the main patient does **not** have a history of pacemaker placement. In the main patientâ€™s profile, there is no mention of any previous cardiac arrest or arrhythmias that would typically necessitate a pacemaker intervention. Additionally, among similar patients, there is no evidence suggesting that a history of pacemaker placement correlates with their outcomes in light of their surgical histories and recent complications. The XGBoost model's output indicating a very low probability (0.00071394) of the occluded outcome further supports this inference, reflecting a strong likelihood that the patient's history does not include pacemaker placement.",1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01765855].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided information, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model estimates a low probability (0.0177) for the patient having this diagnosis, indicating a strong likelihood that they do not. Furthermore, none of the similar patients, which share comparable surgical histories and clinical features, have reported seizures or received antiepileptic medications. This trend supports the model's prediction and suggests a lower risk of seizures in this cohort. Thus, given both the model's performance metrics and the historical data from similar patients, it's reasonable to conclude that the main patient is unlikely to have this diagnosis.","Based on the available data, it is predicted that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model provides a very low estimated probability (0.01765855) for the occluded outcome indicating seizures, which suggests that the likelihood is significantly low. Additionally, examining the similar patients indicates that while some have a history of neurological issues, none among the closely related cohort demonstrate a strong association with seizures given their surgical and clinical profiles. Moreover, the main patient has not shown any history of stroke or significant brain-related complications, which further supports the prediction that they are unlikely to have a diagnosis requiring such treatment.",1,1,0
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.92140007].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? yes\n Did the patient receive a heart transplant? yes\n'],"I predict that the main patient received a heart transplant (yes). The patient's medical history reveals several critical interventions, including a Berlin heart VAD placement in October 2020, which often precedes transplant evaluations in cases of deteriorating heart function. Furthermore, the similar patients who also underwent Fontan procedures exhibited trends suggesting that those with ongoing complications, such as elevated pressures and significant arrhythmias, ultimately required transplantation. The XGBoost model supports this prediction, giving a high probability (0.9214) for the outcome being 'yes,' indicating strong confidence in the necessity of a heart transplant given the current clinical landscape for this patient.","Based on the information provided, I predict that the main patient **did receive a heart transplant**. The patient's surgical history indicates multiple complex interventions, including a Berlin Heart VAD placement and the management of severe complications such as tricuspid regurgitation and fluid overload, which are common in single-ventricle patients. Importantly, many of the similar patients have received transplants, especially those who exhibited a decline in cardiac function or significant complications following Fontan procedures. The XGBoost model prediction also supports this likelihood, with a high estimated probability (0.92140007) suggesting a strong correlation between the patient's characteristics and the likelihood of having undergone a heart transplant. Given the context and data trends, it is reasonable to conclude that the main patient ultimately transitioned to transplant due to their complex medical history.",1,1,1
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0012969].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the information provided, the predicted outcome for the main patient regarding the history of pacemaker placement should be ""**no**."" Although the main patient has undergone multiple surgeries and interventional procedures, there is no documented history of a pacemaker placement in their clinical or surgical history. Furthermore, similar patients with comparable profiles often displayed either the absence of pacemaker placement or reserved placements for more severe arrhythmias, suggesting that the main patient is less likely to have a remote history warranting such an intervention. Additionally, the XGBoost model's prediction of a very low probability (0.0012969) of the occluded outcome indicates consistency with the absence of a pacemaker infection in this patient's clinical history, reinforcing the prediction that the patient has not needed this intervention.","Based on the main patient's provided data, there is no recorded history of pacemaker placement, which is consistent with some of the similar patients analyzed. Among the similar patients, a notable trend shows a prevalence of pacemaker placements in those who had complex surgeries and arrhythmias, yet several patients with a history of Fontan surgery and their associated interventions did not require pacemaker placement. Specifically, in the similar patients, while some had a history of significant arrhythmias, none had indications suggesting they needed a pacemaker after their complex surgeries. Furthermore, the XGBoost model suggests a very low probability (0.0013) of the occluded clinical outcome (history of pacemaker placement) being 'yes'. Therefore, it is reasonable to conclude that the main patient most likely does not have a history of pacemaker placement.",1,1,0
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.8911593].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, I predict that the occluded outcome, â€œHas the patient died?â€ is likely to be ""No."" The main patient has a complex surgical history with multiple cardiac interventions but has shown resilience, as evidenced by surviving a heart transplant without recent reported fatal events. Notably, the XGBoost model indicates a high predicted probability (0.8911593) for the outcome being 'no,' suggesting strong evidence favoring survival. Furthermore, similar patients exhibit varying outcomes but none have reported mortality, despite complications, indicating a trend of surviving beyond their surgeries. This positive trend, combined with the main patientâ€™s continued management of their condition, supports the prediction that they are alive.","Based on the provided data, it is predicted that the outcome for the main patient, specifically whether the patient has died, is **""no""**. This conclusion is supported by the high predictive probability of the XGBoost model, which estimates a probability of 0.891, indicating a strong likelihood that the occluded outcome did not occur. Additionally, the main patient has undergone significant surgeries and interventions but has notable heart function issues (like severe tricuspid regurgitation and ejection fraction around 40%) without historical fatal events. Comparing similar patients, most exhibiting complex cardiac histories, none reported mortality, particularly those with similar surgical histories and clinical features. The trends observed suggest resilience in this cohort, further supporting the prediction that the main patient has not died.",1,1,0
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.63075835].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided information and the XGBoost model's prediction of a 0.63 probability for the occluded outcome of ascites (> trace), itâ€™s reasonable to predict that the main patient likely does have a history of ascites. The patientâ€™s surgical history indicates a series of complex interventions, including placement of a Berlin heart VAD, which suggests significant cardiac compromise that could lead to fluid retention issues like ascites. Additionally, similar patients who underwent the Fontan procedure showed an increased prevalence of ascites, particularly those with increased Fontan pressures and venous congestion resulting from cardiac anatomy. Given these indicators, it is probable that the main patient has experienced similar complications, supporting the predicted outcome of ""yes"" for ascites.","Based on the data provided for the main patient, there is a previous history of pleural effusions but no explicit mention of ascites. However, the patient's complicated surgical history, including multiple interventions and a history of cardiorespiratory distress, may correlate with increased risk factors leading to ascites. In evaluating similar patients, those with histories of right heart dysfunction, cardiac interventions such as fenestration closures, and problematic pulmonary circulation trends also report instances of ascites, suggesting a pattern. Coupled with the XGBoost model's prediction probability of 0.63075835, which suggests a significant likelihood of the outcome being 'yes,' it is reasonable to predict that the main patient likely has a history of ascites (> trace).",1,1,1
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05658219].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the analysis, it is predicted that the main patient **does not have a diagnosis of seizures requiring antiepileptic medications** (no). The XGBoost model's predicted probability of the outcome being 'yes' is very low at 0.05658219, which strongly suggests that seizures are unlikely in this cohort. Additionally, among the similar patients, most who underwent extensive surgical interventions and had complex cardiac histories do not show evidence of seizure activity, and only a small minority had a history of seizures or required antiepileptic medications. Furthermore, the main patient's clinical history, characterized primarily by fluid overload and cardiac anomalies rather than neurological issues, supports this conclusion.","Based on the data provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model's predicted probability of 0.056 indicates a low likelihood that this outcome is present, backed by a validation set with high accuracy and a robust AUC of 0.86. Furthermore, examining the histories of similar patients reveals that those with a history of seizures generally had significant pre-existing neurological events tied to acute cardiac issues, which are not mentioned in the main patient's extensive surgical and clinical history. Therefore, the combined analysis of model predictions and historical patient trends leads to the conclusion that seizures requiring antiepileptic treatment are unlikely for the main patient.",1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00177462].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the information provided, it is predicted that the main patient does **not** have a history of pacemaker placement. This conclusion stems from the patient's comprehensive clinical and surgical history, which includes multiple cardiac surgeries but no mention of complications that would necessitate a pacemaker, such as arrhythmias or significant post-Fontan electrophysiologic study findings. Additionally, the similar patients analyzed typically displayed comparable hemodynamics without requiring pacemakers, especially given the successful Fontan outcomes observed across the cohort. Furthermore, the XGBoost model's estimate of a very low probability (0.00177) for the occluded outcome suggests that pacemaker placement is unlikely for this patient, aligning with the overall data trends.","Based on the provided information and data from similar patients, it is likely that the main patient does not have a history of pacemaker placement (""no""). The main patient has undergone significant cardiac interventions consistent with complex congenital heart disease and has maintained a stable condition with no evidence of arrhythmias that would typically necessitate a pacemaker. Furthermore, among the similar patients with comparable surgical histories and outcomes, none have a record of pacemaker placement, which suggests the absence of extensive conduction issues in this cohort. Additionally, the XGBoost model predicts a very low probability (0.00177) of the occluded outcome being affirmative, indicating strong confidence that this patient does not have a history of requiring a pacemaker.",1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00865501].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the information provided, the predicted missing clinical outcome for the main patient regarding whether they received a heart transplant is **""no.""** 

The XGBoost model predicts a very low probability (0.0087) for the occluded outcome of receiving a heart transplant, suggesting that it's highly unlikely to have occurred. Additionally, examining the surgical history of similar patients who also underwent Fontan operations, many did not receive transplants, especially those with similar diagnoses such as hypoplastic left heart syndrome. The absence of significant complications such as severe ventricular dysfunction or protein-losing enteropathy, which are often precursors to transplantation, also supports the likelihood that transplantation was not necessary in this patient's course. This combined evidence strongly aligns with the model's prediction.","Based on the provided information, I predict that the main patient did **not** receive a heart transplant. The XGBoost model indicates a low predicted probability (0.0087) for the outcome being 'yes', which suggests that the model assesses the likelihood of transplant as quite low given the patient's characteristics. Furthermore, examining similar patients, many with comparable surgical histories and the same diagnosis of hypoplastic left heart syndrome, none of them have had heart transplants reported. This further supports the prediction that it is unlikely for the main patient to have undergone this surgical intervention.",1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02600487].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the patient's clinical and surgical history, as well as the insights derived from the similar patients, it is predicted that the main patient does **not** have a history of ascites (> trace). The MRI report indicates a complex surgical history including a Fontan procedure with a fenestration, which may influence fluid dynamics and the potential for ascites. However, the similar cohort of patients, with overlapping characteristics like the diagnosis of hypoplastic left heart syndrome and a history of multiple surgeries, shows that the majority do not have a history of ascites, consistent with the lower probability given by the XGBoost model (0.02600487). Thus, it appears that this patient is likely to align with that trend, particularly since available data for other patients shows similar preoperative and postoperative scenarios without significant ascitic complications.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). The XGBoost model indicates a low probability (0.026) for the occluded outcome to be 'yes', suggesting that the model is highly confident that this patient does not experience ascites given its accuracy and performance metrics. Additionally, examining the similar patients, none exhibit significant histories of ascites. This consistency across similar patients, along with the overall low predicted probability, supports the conclusion that it is unlikely for the main patient to have a history of ascites.",1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01556012].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model yields a low probability (0.0156) for this outcome, indicating that it's unlikely to occur given the patient's specific clinical features. Additionally, similar patients, particularly those with comparable surgical and MRI profiles, showed low occurrences of seizure-related diagnoses, especially in cases like the main patient who exhibited a history devoid of significant neurological disturbances. Lastly, the main patient's stable clinical status and absence of prior strokes or other neurological complications support this conclusion, aligning with the model's predictions and the observed trends in similar cohorts.","Based on the data provided, I would predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model indicates a very low predicted probability (0.01556012) for this outcome, which suggests that the model does not expect it to occur, especially given the high accuracy and robust performance metrics it has achieved, particularly in identifying non-occurrence of this condition. 

Furthermore, in the empirical evidence from the similar patients, none have reported seizures or related diagnoses, indicating a trend that supports the predicted outcome. The main patient's detailed surgical history, which includes multiple corrective procedures without complications related to seizures, also aligns with the more favorable outcomes observed in similar patients. Overall, while seizures can be a risk in post-Fontan patients, both the model data and the surgical history point towards a lower likelihood for this specific patient.",1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07301246].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, particularly the XGBoost model's predicted probability of 0.07301246 for the outcome ""Has the patient died?"", it indicates a low likelihood of the patient having died (given that values close to 0 suggest non-occurrence). Additionally, the main patient's profile shows a complex surgical history typical of single-ventricle patients, including an Extracardiac Fontan with fenestration, which often results in better survival outcomes compared to those without such interventional strategies. 

The similar patients exhibit survival rates with low mortality rates; none of them died according to the available updates. Collectively, these pieces of information support the conclusion that the main patient is likely still alive, leading to the prediction that **the patient has not died**.","Based on the available data, it is likely that the main patient has not died. Firstly, the XGBoost model estimated a low probability of the occluded outcome (death) at approximately 7.3%, which indicates that the model believes the likelihood of death is minimal among similar cases. Additionally, the surgical and clinical history of the main patient shows no evidence of severe complications that could lead to death, such as significant clot events or severe arrhythmias, as reflected by the absence of a history of cardiac arrest or major vascular thrombus. Finally, similar patients have also demonstrated resilience post-surgery (none have reported death), further supporting the prediction that the main patient is alive.",1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00116448].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the available data, I predict that the main patient did not receive a heart transplant. This conclusion aligns with the XGBoost model's predicted probability of 0.00116448 for the outcome indicating a heart transplant, which is a very low likelihood suggesting it did not occur. Furthermore, when analyzing similar patients, there seems to be a trend where those who share the same surgical history and cardiac diagnoses, particularly those that have undergone Fontan surgery and do not have significant revisions or complications, also did not receive heart transplants. The absence of significant adverse events, along with a robust functional status indicated by the patient's NYHA class and clinical evaluations, supports the likelihood of him remaining stable without the need for transplantation.","Based on the available data, it is predicted that the main patient did **not** receive a heart transplant. The XGBoost model's predicted probability of transplant occurrence is very low at 0.00116448, which suggests that the chances of this outcome are negligible. Additionally, the main patient has a complex surgical history, including a lateral tunnel Fontan and other interventions like oversewing of the pulmonary valve and various collateral interventions. Among the similar patients, none displayed a direct history of heart transplant, and many had significant comorbidities and medical interventions that resulted in stable management of their conditions without necessitating transplantation. This reinforces the conclusion that a heart transplant is unlikely for the main patient in comparison to their cohort.",1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00193613].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the available data for the main patient, it is predicted that they **have not died**. The patient has a complex surgical history, including high-risk features such as Fontan surgery and history of interventions without significant complications reported. The provided model predicts a very low probability (0.0019) of the occluded outcome (death) occurring based on the clinical features. Furthermore, similarities can be drawn from the cohort of similar patients: none of the other patients in the comparable group, which includes some with similar cardiac diagnoses and surgical histories, exhibit a fatal outcome, suggesting a trend of survival amid complex interventions. This reinforces the notion that the patient is likely living, especially considering the absence of critical post-operative complications such as intracardiac thrombus or significant arrhythmias that would suggest a higher mortality risk.","Based on the analysis, I would predict that the main patient has **not** died (no). The XGBoost model estimates a very low probability of death (0.00193613), suggesting that the likelihood of the occluded outcome (death) is minimal. Additionally, examining the similar patients, particularly those with tricuspid atresia and comparable surgical histories, demonstrates that many have achieved favorable outcomes after Fontan surgery, further supporting this prediction. The absence of significant adverse events, along with the high AUC-ROC score of the predictive model, points to stability and resilience in this patient's condition following surgical interventions.",1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01077081].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the data provided, I would predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model yields a low predicted probability (0.01077081) of the occluded outcome being 'yes,' which suggests that seizures are highly unlikely in this context. Furthermore, the similar patients show a pattern where most do not have a history of seizures, and the instances of intracardiac or major vascular thrombus, which could be associated with seizure activity, are also limited in the similar cohort. Thus, the combination of low predictive probability from the model and the clinical trends in similar cases supports the prediction that the main patient does not experience seizures.","Based on the XGBoost model's predicted probability of 0.01077081, which strongly suggests that the occluded outcome (diagnosis of seizures requiring antiepileptic medications) did not occur, and considering that the majority of similar patients did not present with a history of seizures, we predict that the main patient does not have this diagnosis. The model's high accuracy of 0.94 and an AUC-ROC score of 0.86 indicate that it is reliable when evaluating outcomes in this population. Furthermore, the main patient has a clean surgical history without previous cardiac arrest or major complications, further supporting the conclusion that a diagnosis of seizures is unlikely. Thus, it is reasonable to conclude that the patient does not have seizures requiring antiepileptic medications.",1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00066778].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided clinical data, the predicted outcome is **no**, indicating that the patient does not have a history of pacemaker placement. The main patient has undergone multiple surgeries, including a Fontan procedure, without any record of cardiac rhythm issues or interventions that typically lead to pacemaker placement. Moreover, examining the similar patients reveals that pacemaker usage was low, and the current patient demographic, characterized by Tricuspid atresia and a lack of atrial or ventricular arrhythmias, aligns with this trend. Given that the XGBoost model predicts a very low probability (0.00066778) for a history of pacemaker placement, this reinforces the conclusion that it is unlikely in this case.","Based on the information provided, I predict that the main patient does **not** have a history of pacemaker placement. The patient's surgical history indicates a Fontan procedure and various interventions, but there is no mention of pacemaker placement, which aligns with the data from similar patientsâ€”most notably, those who have undergone similar surgeries without requiring a pacemaker. Furthermore, the XGBoost model's output suggests an extremely low probability (0.00066778) for the occluded outcome of a history of pacemaker placement, reinforcing the likelihood that the patient has not required one. Overall, the absence of complications or prior mention of pacing in both the main patient and similar cohorts supports this conclusion.",1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01096194].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the data provided, I would predict that the main patient **does not have a history of ascites (> trace)**. The main patient has a previous MRI report indicating hepatic changes consistent with Fontan-related liver disease, but there is no explicit documentation of ascites. Furthermore, when considering the similar patients, those with comparable surgical histories (such as having Tricuspid atresia and lateral tunnel or extracardiac Fontan procedures) show variable outcomes regarding ascites; however, the XGBoost model's estimated probability of 0.01096 for a history of ascites suggests that such occurrences are relatively rare among patients with similar profiles, supporting the notion that it is unlikely in this case. Additionally, the similar patients also show a tendency toward no significant complications like pleural effusions or ascites. Thus, the combination of the main patient's specific data and the trends observed in similar individuals points toward a conclusion of no significant history of ascites.","Based on the data provided for the main patient and the trends observed in similar patients, it is predicted that the main patient does **not** have a history of ascites. The main patient has a clinical history of Fontan-associated liver disease, which can lead to hepatic complications but does not directly correlate with the presence of ascites. In the cohort of similar patients, several have reported conditions such as protein-losing enteropathy and elevated liver fibrosis tests, which are often associated with ascites. However, those patients did not exhibit the elevated percentages of liver-related problems as a consistent trend among those without a history of ascites. Additionally, the XGBoost model's prediction shows a very low probability (0.01) of the occluded outcome occurring, indicating that ascites is likely not present. This combined evidence points to the conclusion that the main patient likely does not have a history of ascites greater than trace.",1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.04286864].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the data provided, the main patient has undergone multiple complex cardiac surgeries, including a Fontan procedure, and has a right ventricular morphology, which corresponds to a higher risk for complications, including neurological issues like seizures. The XGBoost model predicts a very low probability (approximately 0.0429) for the occluded outcome of having a diagnosis of seizures requiring antiepileptic medications, suggesting that the model indicates a favorable outcome in this regard. However, examination of the similar patients reveals that a few had diagnoses of seizures, particularly those with complex histories similar to the main patient's. Given these factors, while the model suggests a low likelihood of seizure diagnosis, the complexity of the patientâ€™s medical history raises concerns enough to predict that the patient could indeed have a diagnosis of seizures, leading to a reasonable conclusion that the best answer would be ""yes."" 

In essence, the observed complexities and some instances in similar patients have swayed the prediction towards recognizing that despite the modelâ€™s prediction, one cannot completely rule out the potential need for antiepileptic medications in this patient population. Therefore, the final prediction is **yes** for the diagnosis of seizures requiring antiepileptic medications.","Based on the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model predicts a low probability of 0.04286864 for the occluded outcome (""yes""), indicating it is highly unlikely. Additionally, none of the similar patients with comparable surgical histories and cardiac diagnoses exhibit a diagnosis of seizures, which might suggest a trend in this cohort. The patientâ€™s multiple surgical interventions, including a recent biventricular conversion and no documented history of seizures thus far, further support the prediction that seizures are unlikely as a complication stemming from their chronic condition.",0,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00150152].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the available information, it is highly likely that the main patient does not have a history of pacemaker placement. The main patient has undergone several surgeries including a biventricular conversion and various interventions related to their double outlet right ventricle, but there is no mention of a pacemaker in their surgical history, which is supported by their stable current status without significant arrhythmic concerns. 

Looking at the similar patients, most of whom have complex heart conditions and varying interventions, only a small proportion reported pacemaker placements, often linked to the severity of their cardiac dysrhythmias or complications related to surgical outcomes. The XGBoost model predicts only a 0.0015 probability of the occluded outcome (""history of pacemaker placement"") being positive, suggesting that the model indicates a strong inference against the presence of such history. Therefore, combining clinical context with data trends, the conclusion can be drawn that the patient likely does not have a history of pacemaker placement.","Based on the available data, the predicted outcome for whether the main patient has a history of pacemaker placement is ""no."" The main patient has undergone several surgeries, including a recent biventricular conversion in 2017, which typically does not mandate the placement of a pacemaker unless there are specific complications or rhythm issues that necessitate it. Additionally, the patientâ€™s current status shows no history of arrhythmias or need for electrophysiologic studies, which could suggest that their cardiac rhythm remains stable. The similar patients analyzed all have varied surgical histories and outcomes, but none indicated a need for pacemakers in the context presented, implying a low likelihood of this patient needing one as well. Thus, combining the clinical history and the exemplar data suggests it is reasonable to conclude that the patient does not have a pacemaker.",1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00720092].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"**Prediction for the Missing Clinical Outcome:** **No**, the patient does not have a history of ascites (> trace).

**Reasoning:** The main patient has a documented history of multiple surgeries including a Fontan procedure and notable interventions but shows no signs of ongoing complications typically associated with ascites, such as liver dysfunction or prior episodes of fluid retention. In examining the similar patients, particularly those with complex congenital heart defects comparable to the main patient's condition, there appears to be a trend where those without documents of significant fluid retention or related symptoms do not harbor a history of ascites. Furthermore, the XGBoost model, which estimates a very low probability (0.0072) for a history of ascites occurring, reinforces the finding that ascites is unlikely in this case, thus suggesting that the patient has not experienced ascites related complications.","Based on the data provided for the main patient, including their extensive surgical history related to congenital heart disease and the absence of previous diagnoses related to fluid retention or related complications, it is reasonable to predict ""no"" for the occluded outcome regarding a history of ascites (> trace). Additionally, the similar patients' records generally do not indicate a significant association between their surgical interventions and the development of ascites, especially given that none of them reported such symptoms in conjunction with their complications or diagnoses. Furthermore, the XGBoost model's predicted probability of ""yes"" (0.0072) strongly supports a low likelihood of ascites as an issue in this patient. Therefore, integrating clinical evidence and predictive analytics, I conclude that the missing clinical outcome is likely ""no.""",1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00189202].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, the predicted clinical outcome for the main patient is **""no""**; they did not receive a heart transplant. The XGBoost model's estimated probability for the outcome being ""yes"" is 0.00189202, which is extremely low and indicates a strong likelihood that the patient did not receive a heart transplant. Additionally, among the similar patients, many also did not receive a transplant despite similar surgical histories and complicated cardiac diagnoses, suggesting a trend where patients with multiple surgeries but no evidential progression toward transplant may tend to continue managing their conditions palliatively rather than opting for transplantation. Furthermore, the main patient's extensive surgical history and current status without transplantation align with the procedural and clinical insights drawn from the similar patient cohort, reinforcing the predictive model's conclusion.","Based on the available data, it is reasonable to predict that the main patient did **not** receive a heart transplant. The XGBoost model gives a predicted probability of 0.0019 for the outcome being 'yes,' which indicates a strong likelihood that the patient did not undergo transplantation. Furthermore, similar patients with analogous surgical histories, particularly those who also underwent the Fontan procedure, display a trend of not receiving a heart transplant, suggesting that they were managed through other interventions. Additionally, the presence of significant cardiac abnormalities, such as tricuspid atresia or hypoplastic left heart syndrome, typically leads to consideration of heart transplantation in cases of severe heart failure, but since the main patient's status shows no critical reports or escalated complications prior to this evaluation, it aligns with the prediction that a transplant was not necessary.",1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00420783].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the available data and the predicted probability from the XGBoost model (0.0042), it is reasonable to conclude that it is highly unlikely the main patient has died, leading to a prediction of ""no"" for the occluded outcome, ""Has the patient died?"". The model's excellent performance metrics, including an accuracy of 0.96 and a notably high precision for predicting those who have not died (0.97), support this conclusion. 

Furthermore, the main patient's medical and surgical history, including successful completion of multiple corrective surgeries (Fontan procedure and subsequent interventions), and the lack of documented severe complications or adverse events (e.g., no history of cardiac arrest or significant thrombus), align with the trends observed in the similar patients' histories, which predominantly include those who remain alive. Overall, these findings together suggest a favorable clinical course for the main patient.","Based on the provided data, I predict that the main patient has **not died**. This conclusion is supported by the XGBoost model's predicted probability of the occluded outcome being 'yes' being only 0.00420783, indicating a low likelihood of mortality. Furthermore, the patientâ€™s surgical history showcases several significant interventions associated with ongoing management for congenital heart disease, yet there is no record of fatal complications or significant morbidities in their status updates. When considering similar patients, most with comparable surgical histories also demonstrated surviving outcomes, with a noted trend of utilizing effective interventions like Fontan procedures and ongoing care management to sustain their health post-surgery.",1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9956909].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the analysis of the main patient's data and the similar patientsâ€™ characteristics, the prediction is that the patient **does not have a history of pacemaker placement**. The main patient has undergone extensive procedures consistent with complex congenital heart disease, including multiple surgeries and interventions, but notably, no mention of a pacemaker or any related symptoms suggesting the need for one. 

In examining similar patients, many also exhibited extensive surgical histories without evidence of pacemaker placements, particularly those with comparable surgical historiesâ€”such as those undergoing Fontan procedures. The XGBoost model's high predictive probability (0.9957) reinforces confidence in this assessment, suggesting that a pacemaker was likely not necessary given the patient's current clinical status and previous outcomes.","**Prediction:** Yes, the patient has a history of pacemaker placement.

**Reasoning:** The main patient underwent multiple complex cardiac surgeries, including a Fontan procedure, and has a history indicative of potentially significant arrhythmogenic complications, such as prior cardioversion for wide complex tachycardia. Additionally, among the similar patients, a notable trend shows that many have required pacing interventions due to arrhythmias or other complications linked to similar surgical histories involving single-ventricle physiology and similar cardiac anatomies. Given the high prediction probability from the XGBoost model (0.9956909) and the clinical context, it is reasonable to conclude that the patient likely has a history of pacemaker placement.",0,1,1
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01524258].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, the prediction for the occluded outcome ""Has the patient died?"" is **no**. The main patient has a complex cardiac history but has maintained a stable status, with no reports of significant complications such as sudden cardiac arrest, major thrombus, or progressive heart failure that often correlate with higher mortality rates. Furthermore, the XGBoost model's predicted probability of 0.015 indicates a very low likelihood of death, supported by the model's high accuracy and precision rates in the validation set. Additionally, similar patients with comparable surgical histories and cardiac diagnoses have not experienced mortality, reinforcing the inference that this patient is likely to have survived.","Based on the provided data, the predicted probability of the outcome ""Has the patient died?"" for the main patient is approximately 0.015, indicating a low likelihood of death. This conclusion is supported by the main patient's surgical history, which includes multiple successful surgeries and an overall stable clinical presentation with no reports of significant complications such as cardiac arrest, intracardiac thrombus, or severe postoperative issues. Additionally, trends observed in similar patients reveal generally positive outcomes and survival, with the majority of them having not died following their respective surgeries. Given these factors, it is reasonable to predict that the main patient has not died.",1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01184468].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the XGBoost model's predicted probability of 0.0118 for the occluded outcome being 'yes,' it indicates that there is a very low likelihood of the main patient experiencing a history of ascites. This aligns with the main patientâ€™s detailed clinical history, which explicitly states no occurrences of ascites, pleural effusion, or complications related to excess fluid build-up post-surgery. 

Furthermore, the similar patients' outcomes predominantly reflect a lack of ascites, especially among those with comparable surgical histories and management (e.g., glen and Fontan procedures). As such, considering the low model prediction combined with clinical context, the most reasoned conclusion is that the main patient does not have a history of ascites.","Based on the provided information, the predicted outcome for the main patient regarding a history of ascites (> trace) is **no**. The XGBoost model gives a probability of 0.0118 for the outcome being 'yes', indicating that there is a very low likelihood of ascites in this patient. Moreover, examining the similar patients, many have a history of various complications associated with single ventricle morphology, but the trend shows minimal cases of ascites among those who underwent Fontan surgeries. The main patientâ€™s surgical history does not include significant interventions associated with fluid retention issues, further supporting the prediction of no history of ascites.",1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00091276].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, I predict that the main patient did **not** receive a heart transplant. The XGBoost model indicates a very low probability (0.00091276) of the occluded outcome being 'yes', suggesting that the model strongly leans towards predicting 'no'. This is consistent with the findings among similar patients, many of whom, including those with comparable clinical histories and surgical interventions, did not receive heart transplants. Furthermore, the main patient's surgical history shows complexities such as multiple previous interventions and ongoing management of arrhythmias, which may indicate a strategy of managing the existing surgical outcomes rather than opting for transplantation. Given these points, it is reasonable to conclude that a heart transplant was not performed for this patient.","Based on the provided data, it is predicted that the main patient did **not** receive a heart transplant. The XGBoost model output indicates a very low probability (0.00091276) for the occluded outcome of receiving a heart transplant, suggesting that it is unlikely based on the clinical features. Additionally, looking at similar patients who had comparable surgical histories (such as those who also underwent Fontan procedures), there is a trend indicating that patients with similar conditions, including a history of single ventricle physiology and multiple interventions, often do not require a transplant, particularly if they have been stable without major complications such as a significant deterioration in heart function or life-threatening arrhythmias. The main patient's absence of critical negative events further supports this conclusion.",1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03238112].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, the prediction for the missing clinical outcome, ""Does the patient have a diagnosis of seizures requiring antiepileptic medications?"" is **no**. 

The main patient has undergone multiple complex cardiac procedures, including Fontan surgery and various interventions without a documented history of seizures or the use of antiepileptic medications, suggesting a lower likelihood of such diagnoses. Additionally, among the similar patientsâ€”many of whom share comparable surgical histories and cardiac diagnosesâ€”there is a notable absence of seizure diagnoses, with one patient reported having no such history. The XGBoost model further predicts a low probability of this outcome occurring (0.032), indicating strong confidence in a negative diagnosis related to seizures.","Based on the information provided, the prediction for the missing clinical outcomeâ€”whether the patient has a diagnosis of seizures requiring antiepileptic medicationsâ€”is **no**. The main patient has a complex cardiac history but noteworthy is the absence of recorded occurrences of seizure activity, stroke, or significant arrhythmias that would typically correlate with such a diagnosis. In contrast, similar patients who experienced seizures often had a history of more profound neurological events or cardiac management interventions likely associated with higher risks of seizures. Additionally, the low predicted probability of 0.03238112 from the XGBoost model, along with its high accuracy and AUC-ROC score, indicates a strong tendency to predict 'no' for this particular outcome in cases like the main patient's.",1,1,0
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.3319198].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.96
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.87

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the available data, it is predicted that the missing clinical outcome, ""Has the patient died?"" will be **no**. The main patient has a complex surgical history, including multiple surgeries related to Fontan and has not been reported to have a significant number of complications typically associated with mortality, notably intracardiac or major vascular thrombus, seizure, or severe pulmonary issues. The XGBoost model's predicted probability of death is relatively low (0.3319198), which suggests that the patient is more likely to be alive than deceased. Additionally, the similar patients generally show a trend of surviving post-Fontan procedures, further supporting the likelihood of the main patient being alive.","Based on the data provided for the main patient, it seems that they have had a complex surgical history associated with single-ventricle physiology, which includes multiple cardiac surgeries and complications, but they have survived those interventions. The similar patients, despite some having complex diagnoses and histories of complications, predominantly show no incidences of death, further supported by an analysis of the prediction model. The XGBoost model predicts a probability of 0.3319198 for the outcome ""Has the patient died?"" to be yes, but considering the high accuracy rate of 0.96 and the relatively low count of fatalities in similar cases, it is reasonable to conclude that the main patient has not died. Therefore, the predicted outcome is ""No,"" indicating the patient is still alive.",1,1,0
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9933822].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 1.00
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 1.00

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the analysis of the main patientâ€™s data in conjunction with the similar patients, it is reasonable to predict that the main patient does have a history of pacemaker placement, thus the answer is **yes**. The main patient exhibits significant cardiac history and interventions, including multiple surgeries related to Fontan procedures, which often correlate with complex arrhythmias or conduction disturbances, potentially necessitating pacing. Additionally, among similar patients identified, many have undergone pacemaker placements associated with similar surgical histories and complications, further suggesting a high probability in this case. The high predicted probability (0.993) from the XGBoost model supports this conclusion, indicating a strong likelihood that this specific outcome occurred for the main patient.","Based on the provided data, the predicted clinical outcome for the main patient regarding the history of pacemaker placement is ""yes."" This conclusion is supported by several factors: firstly, the patient has a complex surgical history, including multiple cardiac interventions and revisions, which often increases the likelihood of requiring a pacemaker due to potential rhythm disturbances. Additionally, in the cohort of similar patients, there are instances where complex congenital heart surgical histories correlate with the requirement for pacing devices. The XGBoost model's high predictive probability of 0.9933822 reinforces this assessment, suggesting a strong association between the patient's extensive surgical procedures and the need for a pacemaker. Thus, it is reasonable to conclude that this patient likely has a history of pacemaker placement.",1,1,1
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.17247081].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.94
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.86

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? yes\n'],"Based on the analysis of the main patient's data alongside the trends observed in similar patients, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient has a history of significant cardiac surgeries, including various Fontan procedures, and the insights from similar patients also show an overall low incidence of seizure diagnoses in this cohort. The XGBoost model estimated a probability of 0.172 for the occluded outcome being positive, indicating a low likelihood of this diagnosis occurring. Additionally, none of the similar patients described had a diagnosis of seizures, reinforcing the assumption that it is less common in this clinical context. Overall, the evidence strongly suggests the outcome is likely a **no**.","I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model's predicted probability of 0.172 indicates a low likelihood that this diagnosis applies, suggesting that seizures are relatively rare among patients with similar profiles. Furthermore, examining the outcomes of similar patients, especially considering their surgical histories (which include multiple complex interventions like the Fontan procedure and interventions related to their specific cardiac diagnoses), shows that although there are some cases of intracranial thrombus or significant neurological interventions resulting in seizures, the majority do not present with seizures as a complication. This trend reinforces that while neurological issues can arise in these complex surgical cases, they do not occur uniformly, and thus the overall assessment suggests a lower likelihood of seizure diagnosis in the main patient.",0,0,1
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.32011402].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.93
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.88

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the predicted occluded outcome for the main patient is ""no"" for the history of ascites (> trace). The main patient does not have a documented history of ascites and reports experiencing pleural effusions, which differ from ascites in terms of underlying pathology and implications. Furthermore, the similar patients, particularly those with hypoplastic structures and comparable surgical histories, show a trend where those with similar cardiac conditions and histories do not commonly report significant ascitic complications, as seen with the similar cohort predominantly without significant ascites history. The estimated probability from the XGBoost model (0.32) further aligns with this conclusion, suggesting that while there is some risk associated with similar patients, the majority, including the main patient, reflect a lesser incidence of ascites than the model's threshold would typically suggest. Thus, the comprehensive assessment leads to the conclusion that the patient likely does not have a history of ascites.","Based on the data provided, I would predict that the main patient likely does **not** have a history of ascites (> trace). The main patient has a significant surgical history related to aortic and valve procedures, along with a total of five cardiac surgeries, but there is **no reported history of ascites**. Meanwhile, among the similar patients whose profiles match closely, the trend shows that while some have vascular abnormalities or complex histories, the average prevalence of ascites is relatively low, and the occluded outcome prediction from the XGBoost model indicates only a 32% probability of having this condition. Therefore, considering both the main patientâ€™s current health status and the insights from similar cases, it seems reasonable to conclude that the main patient does not exhibit a history of ascites.",1,1,0
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? yes
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00805685].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.

The XGBoost model performs very well so take it's prediction with a lot of weight. Specifically, it achieved the following performance metrics on the validation set (excluding the test patient):
 - Accuracy: 0.98
 - Area Under the Receiver Operating Characteristic (AUC-ROC) Curve: 0.93

In this model, a predicted value of 0 indicates the model predicts the occluded outcome did not occur for a given patient, while a predicted value of 1 indicates the model predicts it did occur.

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, the predicted clinical outcome for the main patient regarding whether they received a heart transplant is ""no."" The XGBoost model's estimated probability of 0.00805685 suggests a very low likelihood of receiving a transplant, which is reinforced by the historical data from similar patients. Notably, all similar patients listed did not receive a heart transplant, and they share comparable surgical histories of complex congenital heart disease and interventions like Fontan procedures. Additionally, the main patient's extensive surgical history, including multiple interventions and ongoing management of complications, suggests that while the clinical situation is serious, it has not escalated to the point necessitating a transplant. Overall, the combination of the model's prediction and the insight gained from similar cases leads to a confident conclusion that the main patient did not receive a heart transplant.","Based on the provided data, the prediction for the main patient is that they **did not receive** a heart transplant. The XGBoost model estimates the probability of having received a heart transplant as only 0.0081, indicating a high confidence that the outcome did not occur. This aligns with the main patient's surgical and clinical history, which details multiple interventions related to a complex congenital heart defect but does not indicate a heart transplant, a measure typically reserved for the most severe cases. Furthermore, looking at the similar patients, many who had complex surgical histories like the main patient did not receive heart transplants, suggesting a consistent trend of managing congenital heart issues without resorting to transplantation.",1,1,0
